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Rationale: 3,4-methylenedioxymethamphetamine (MDMA) is a less efficacious 
reinforcer than other drugs of abuse. However, following repeated self-administration, 
responding increases for some animals and efficacy becomes comparable to other 
drugs of abuse. MDMA-stimulated serotonin (5-HT) release was negatively associated 
with acquisition of MDMA self-administration, and a neurotoxic 5-HT lesion reduced 
the latency to acquire self-administration. These findings suggest that MDMA-
produced 5-HT release is an important component of self-administration. The receptor 
mechanisms are not, however, well understood, although it has often been suggested 
that the mechanism involves 5-HT-mediated inhibition of dopamine. Both 5-HT1A and 
5-HT1B receptors are well localised to regulate dopamine release, and both have been 
implicated in modulating the reinforcing effects of many drugs of abuse.  
Objectives: The first objective was to establish specific behavioural assays to reflect 
5-HT1A and 5-HT1B receptor activation. Then, using the established behavioural 
assays, the aim was to determine the role of 5-HT1A and 5-HT1B receptors in the 
acquisition of MDMA self-administration. The impact of substantial MDMA self-
administration on 5-HT1A and 5-HT1B receptors was also assessed. 
Methods: Firstly, dose-effect relationships for the hyperactive response to the 5-HT1A 
receptor agonist, 8-OH-DPAT (0 – 3.0 mg/kg) and the hyperactive and adipsic 
response to the 5-HT1B/1A receptor agonist, RU 24969 (0 – 3.0 mg/kg) were 
determined. Selectivity of these responses was determined by co-administration of the 
5-HT1A receptor antagonist, WAY 100635, or the 5-HT1B/1D receptor antagonist, GR 
127935. Secondly, a pretreatment regimen of the RU 24969 (2 × 3.0 mg/kg/day, 3 
days), which had been suggested to down-regulate 5-HT1B/1A receptors, was 
administered prior to self-administration testing. The effect of this manipulation on 
both the acquisition of MDMA self-administration, and the behavioural responses to 5-
HT1A and 5-HT1B receptor activation, was measured. A further study measured 
behavioural responses to 5-HT1A or 5-HT1B receptor agonists prior to self-
administration, to determine whether the variability in these responses would predict 
the variability in the latency to acquisition of MDMA self-administration. Lastly, the 
effect of substantial MDMA self-administration (350 mg/kg) on dose-response curves 
for the behavioural effects of 5-HT1A or 5-HT1B receptor activation was assessed.  
Results: The hyperactive response to the 5-HT1B/1A receptor agonist, RU 24969, was 





antagonist, GR127935. Similarly, the hyperactive response to the 5-HT1A receptor 
agonist, 8-OH-DPAT, was dose-dependently blocked by WAY 100635. GR 127935, 
but not WAY 100635, blocked the adipsic response to RU 24969. 
Repeated administration of RU 24969 produced rightward shifts in the dose-response 
curves for 8-OH-DPAT-produced hyperactivity and RU 24969-produced adipsia, and 
also greatly facilitated the acquisition of MDMA self-administration. However, there 
was no correlation between latency to acquire MDMA self-administration and the 
hyperactive response to 8-OH-DPAT or the adipsic response to RU 24969, and 
MDMA self-administration failed to alter these behavioural response to activation of 
5-HT1A or 5-HT1B receptors.  
Conclusions: The hyperactive response to 8-OH-DPAT and the adipsic response to 
RU 24969 reflect activation of 5-HT1A and 5-HT1B receptors, respectively. The 
variability in acquisition of MDMA self-administration was reduced by a treatment 
that also down-regulated 5-HT1A and 5-HT1B receptors, however there was no further 
indication that these receptors play a critical role in the self-administration of MDMA. 
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Brief history of MDMA 
3,4-methylenedioxymethamphetamine (MDMA) was initially patented by the 
pharmaceutical company, Merck, in 1914 as a precursor for other therapeutically 
efficacious compounds (Green, Mechan, Elliott, O'Shea, & Colado, 2003). Some basic 
preclinical tests were conducted with MDMA in 1927 (Freudenmann, Öxler, & 
Bernschneider-­‐Reif, 2006), and in 1953 the US Army sponsored research on the 
toxicity of MDMA, concluding that further study in humans should be conducted 
(Hardman, Haavik, & Seevers, 1973). In response to the first reports of recreational 
MDMA use (Gaston & Rasmussen, 1972) Alexander Shulgin published the first papers 
outlining the effects of MDMA in humans (Anderson, Braun, Braun, Nichols, & 
Shulgin, 1978; Shulgin, 1978; Shulgin & Nichols, 1978), also encouraging further 
human studies. Shulgin was a vocal advocate for the use of MDMA as an adjunct to 
psychotherapy, but it has been suggested that his public promotion of MDMA also led 





 As recreational use continued to grow, there was pressure on governments to 
bring the use of MDMA under legislative control (Beck & Rosenbaum, 1990). MDMA 
was scheduled as a Class B Controlled Drug in New Zealand in 1987 (New Zealand 
Drug Foundation, 2015), following classification in Schedule I by the USA Drug 
Enforcement Agency in 1985 (Beck & Rosenbaum, 1990). The import, manufacture, 
supply, or administration of Class B Controlled Drugs carries a jail sentence of up to 
14 years in New Zealand (Misuse of Drugs Act 1975). Nonetheless, recreational use of 
MDMA, in the form of the street drug, ‘ecstasy’, is popular in New Zealand (Wilkins, 
2011; Wilkins & Sweetsur, 2008), and around the world (United Nations Office on 
Drugs and Crime, 2015).  
Recently, there has been a revival in the push to harness the subjective effects 
of MDMA in the treatment of psychiatric disorders. Some therapists claim that 
MDMA helps patients talk openly, and fosters an atmosphere of trust (Kupferschmidt, 
2014). Clinical trials are currently underway assessing the utility of MDMA as a 
therapeutic adjunct in the treatment of post-traumatic stress disorder, and anxiety 
associated with a life-threatening illness (National Institutes of Health, 2015). 
MDMA use 
MDMA is generally consumed as the primary psychoactive component of the 
popular street drug, ecstasy (also known as E, Molly, pingers, pills, disco biscuits). 
Ecstasy is most commonly available in tablet form, and tablets are usually either 
consumed orally or crushed for intranasal administration (De La Garza, Fabrizio, & 
Gupta, 2007; Parrott, 2013a; Solowij, Hall, & Lee, 1992). In recent years 
recreationally used ecstasy tablets have been shown to contain a wide range of 
psychoactive substances, including significant quantities of methamphetamine, 
ketamine, caffeine, meta-Chlorophenylpiperazine (mCPP) and mephedrone, and have 
sometimes contained no MDMA whatsoever (Brunt, Koeter, Niesink, & van den 
Brink, 2012; Morefield, Keane, Felgate, White, & Irvine, 2011; Togni, Lanaro, 
Resende, & Costa, 2015; Vogels et al., 2009). Therefore, throughout this thesis, the 
term ‘ecstasy’ will be used to refer to the street drug that generally contains MDMA, 
while ‘MDMA’ will be used to refer specifically to the psychoactive substance. 
 Ecstasy became popular in the underground dance party scene of the 1980s, in 
part because it increases energy levels, heightens sensual awareness, and facilitates 





2000s ecstasy use became more mainstream, becoming a popular recreational drug 
among young adults. A recent study reported worldwide prevalence of ecstasy use to 
be the second highest of all illicit drugs (Global Drug Survey, 2014). Recently, 
popularity of ecstasy has been facilitated by a ‘re-branding’ of ecstasy as ‘Molly’ in 
the mainstream media. ‘Ecstasy’ has associations with the old dance parties of the 
1980s, electronic music, and un-masculine displays of affection, misaligning it with 
the modern zeitgeist which is heavily influenced by pop and hip-hop culture. On the 
other hand, ‘Molly’ has been embraced by the hip-hop and pop communities, 
providing a ‘new’ drug that youth can associate with (Carter, 2016). 
 Although ecstasy use is common, patterns of use differ widely. A recent study 
showed that, of 109 subjects who had recently used ecstasy for the first time, 43 did 
not take ecstasy again in the following 12 months, while 23 consumed more than 10 
ecstasy pills in that time period (Wagner, Becker, Koester, Gouzoulis-­‐Mayfrank, & 
Daumann, 2013), illustrating that some will use ecstasy very infrequently, while others 
will use ecstasy regularly. Furthermore, recent surveys have found a significant 
proportion of regular ecstasy users met Diagnostic and Statistical Manual of Mental 
Disorders (DSM) -IV-based criteria for dependence (Cottler, Leung, & Abdallah, 
2009; Cottler, Womack, Compton, & Ben-Abdallah, 2001; Uosukainen, Tacke, & 
Winstock, 2015). The more recent DSM 5 provides diagnostic criteria for ‘substance 
use disorders’ (SUDs) rather than ‘dependence’ (American Psychiatric Association, 
2013). Although there is no specific ecstasy SUD, some ecstasy users met a number of 
SUD criteria, including using more drug than intended (Cottler et al., 2009; Cottler et 
al., 2001) unsuccessful efforts to cut down on use (Jansen, 1999), craving (A. K. Davis 
& Rosenberg, 2014; Hopper et al., 2006), neglecting activities other than acquiring and 
taking drug (Cottler et al., 2009; Cottler et al., 2001; Jansen, 1999; Yen & Hsu, 2007), 
use in spite of known negative consequences (Cottler et al., 2009; Cottler et al., 2001; 
Jansen, 1999; Schifano & Magni, 1994; Yen & Hsu, 2007), tolerance (Cottler et al., 
2001; Jansen, 1999; Kirkpatrick et al., 2014; Parrott, 2005; Peroutka, Newman, & 
Harris, 1988; Yen & Hsu, 2007), and withdrawal (Cottler et al., 2009; Cottler et al., 
2001; Jansen, 1999; Peroutka et al., 1988). Thus, while some ecstasy users take ecstasy 
relatively infrequently, a subpopulation of users show regular use, and some show 





Harms associated with MDMA use 
The regular use of ecstasy in some users is of concern, not only because of the 
potential to develop an SUD, but also because ecstasy use has been associated with a 
number of cognitive, behavioural, and neurochemical deficits. Ecstasy users showed 
deficits in learning (Wagner et al., 2013), and in attention and memory (McCann, 
Mertl, Eligulashvili, & Ricaurte, 1999) compared to ecstasy-naïve controls or those 
with limited ecstasy use. Ecstasy users reported higher levels of depression, 
impulsiveness, and sleep disturbances than poly-drug users who did not use ecstasy 
(Soar, Turner, & Parrott, 2006; Taurah, Chandler, & Sanders, 2014). These cognitive 
and behavioural deficits were persistent, suggesting that regular ecstasy use may cause 
long-lasting neuroadaptations (Parrott, 2013a, 2013b; Schifano & Magni, 1994). With 
increased experience some heavy ecstasy users report persistent problematic 
behaviour, including paranoid delusions (Schifano & Magni, 1994), severe weight loss 
(Jansen, 1999; Schifano & Magni, 1994), and suicidal thought (Jansen, 1999; Schifano 
& Magni, 1994). 
Ecstasy use has also been associated with deficits in the neurotransmitter, 
serotonin (5-HT). Ecstasy users had decreased 5-HT transporter binding (Kish et al., 
2010; McCann, Szabo, Scheffel, Dannals, & Ricaurte, 1998), reduced levels of the 5-
HT metabolite, 5-hydroxyindoleacetic acid (5-HIAA), in cerebrospinal fluid (McCann, 
Mertl, et al., 1999), reduced 5-HT synthesis in frontal and parietal regions (Booij et al., 
2014), and autopsied striatal tissue from a  heavy ecstasy user indicated decreased 5-
HT and 5-HIAA levels (Kish, Furukawa, Ang, Vorce, & Kalasinsky, 2000). These 
markers of reduced 5-HT function correlate with lifetime ecstasy use (Kish et al., 
2010; McCann et al., 1998) and levels of behavioural impairment (Kish et al., 2010). 
Therefore, it is possible that at least some of these adaptations underlie the long term 
behavioural problems seen after repeated ecstasy use. The mechanisms by which 
MDMA might produce these effects is not clear. 
Problems associated with studying the harmful effects of MDMA 
Given the global popularity of ecstasy, and the deficits associated with regular 
use, it becomes important to investigate potential treatments to reduce intake, and to 
reverse harmful neuroadaptations. However, there are a number of potential confounds 
associated with studies that use human subjects to determine the effects of MDMA use 





limited by a number of factors. For example, the accuracy of subjects’ reported use and 
the range of other drugs the subject also uses may confound results. This concept is 
illustrated in the abovementioned report by Jansen (1999) describing the effects of 
ecstasy use in three regular users, in which total lifetime ecstasy exposure was 
determined by self-report for periods of over two years. This method for determining 
drug intake relies on memory for drug taking episodes even though ecstasy use is 
associated with memory impairments. Furthermore, the study by Jansen highlights the 
poly-drug use typical of regular ecstasy users (Cottler et al., 2009; Cottler et al., 2001) 
– the first patient reported regular amphetamine use of 1g/day, the second was 
dependent on benzodiazepines, while the third consumed roughly 1 bottle of spirits 
every night. Regular use of other drugs makes it more difficult to isolate the effects of 
MDMA. 
A second potential issue with human studies is that varied individual histories 
of ecstasy users can limit the conclusions that can be drawn. For example, while 
symptoms of depression and anxiety are widely reported after regular ecstasy use 
(Rogers et al., 2009), a causal link cannot be drawn between ecstasy use and 
psychological deficits, given that pre-existing problems such as anxiety and depression 
might predispose an individual to regular ecstasy consumption as a form of self-
medication (Parrott, 2006, 2013a). Without random allocation and an appropriate 
control group, causal links between drug use and its effects cannot be drawn. In an 
effort to overcome this limitation a small number of studies have randomly assigned 
participants to receive acute administrations of MDMA, but, as the authors of one 
study lament, ethical constraints on dosing regimens severely limit the ecological 
validity and scope of such studies (Peiró et al., 2013). 
 Some researchers have gone to great lengths to minimise the impact of such 
confounds on the results of their studies. For example, a recent study investigated 
current ecstasy users and compared results to a control group of poly-drug users that 
have never used ecstasy. Thus, any differences should be attributable to ecstasy use. 
The results showed that ecstasy users had higher levels of cognitive and behavioural 
disturbances than non-ecstasy poly-drug users (Taurah et al., 2014). Such results 
strengthen claims that MDMA use is harmful and help to illustrate the nature of these 
harms. However, because of ethical constraints that restrict the doses of MDMA that 
can be administered to humans, investigations into the mechanisms behind these 






For these reasons, animal models are often turned to in order to obtain 
information regarding the effects of exposure to MDMA. The real value of animal 
laboratory studies is that they allow experimenters some control over the histories of 
subjects, the drugs administered, and environmental factors. Furthermore, a wider 
range of doses can be administered to animals than is ethically viable with humans. 
There is some loss of ecological validity when animal models are employed, 
particularly as they necessarily ignore the complex environment in which ecstasy is 
consumed, but such studies can be incredibly helpful in evaluating properties of 
MDMA that cannot be determined in humans.  
A number of studies have replicated the findings of human studies after 
administering MDMA to animals. Typically, high doses of MDMA are administered 
repeatedly, after which some behavioural or neurochemical measures are made. For 
example, exposure to high doses of experimenter-administered MDMA decreased 
tissue 5-HT levels (Battaglia, Yeh, & De Souza, 1988; Commins et al., 1987; 
McGregor et al., 2003), damaged 5-HT cells (Commins et al., 1987; Jensen et al., 
1993), and reduced 5-HT transporter binding (Battaglia, Yeh, et al., 1988; McGregor 
et al., 2003). In behavioural tests, repeated administration of MDMA increased 
anxiety-like behaviour in adult (McGregor et al., 2003) and adolescent rats (Bull, 
Hutson, & Fone, 2003; Bull, Hutson, & Fone, 2004; Cox et al., 2014), and impaired 
novel object discrimination, a measure of recognition memory (Shortall et al., 2013). 
Although this method of experimenter-administered, high dose MDMA is useful for 
determining the harmful effects of MDMA, these studies have been criticised for 
employing a physiologically irrelevant dosing regimen (Baumann & Rothman, 2009; 
Cole & Sumnall, 2003; De La Garza et al., 2007; Meyer, Piper, & Vancollie, 2008), 
given that this high level of exposure is rarely, if ever, experienced by ecstasy users 
(D. Hansen, Maycock, & Lower, 2001; Parrott, 2005; Verheyden, Henry, & Curran, 
2003). 
 One alternative to an experimenter administered drug regimen is to give the 
animal control over the delivery of drug, in a manner similar to how humans control 
their drug intake. This is the basis of the popular self-administration paradigm, in 
which an animal performs some operant (e.g. nose poke, lever press) in order to obtain 
a dose of drug. Often, the route of drug administration is intravenous, meaning the 





this surgery, the animal is placed in an operant chamber and the catheter is connected 
via tubing to a syringe encased in a mechanical syringe pump. The operant activates 
the syringe pump, resulting in a predetermined intravenous dose of the drug being 
investigated. Drug infusions are generally paired with a stimulus (e.g. light, tone). 
Usually there is a second manipulandum (e.g. nose poke hole, lever) for which the 
operant has no programmed consequence, but responses are recorded as a measure of 
non-specific responding.  
 Human drug taking is a complex behaviour that is influenced by an interaction 
of social, economic, and personal factors, and as such it cannot be modelled in a single 
animal paradigm. Furthermore, as with all animal models, ecological validity is lost in 
order to gain experimental control and practicality. For example, self-administration 
studies generally allow an animal to self-administer only the drug of interest (with no 
adulterants), in order to draw causal conclusions about this drug. In contrast, human 
drug users tend to use a range of drugs, and drugs procured on the street tend not to be 
pure. Thus, the self-administration paradigm trades ecological validity for 
experimental control (De La Garza et al., 2007). While experimental design can help to 
minimise the loss of validity, no self-administration model can perfectly replicate 
human drug taking. Nonetheless, as will be explained below, the self-administration 
paradigm is an excellent paradigm for MDMA administration, and also allows for 
studies in which drug taking is the dependent measure. 
 A particular strength of the self-administration paradigm is that the animal has 
control over their drug intake. Firstly, this reduces concerns over the administration of 
irrelevantly large drug doses. Figure 1.1 presents data adapted from Schenk, Gittings, 
Johnstone, and Daniela (2003) showing the number of infusions of MDMA that were 
self-administered in a session, for different doses of MDMA. It is clear that MDMA 
self-administration behaviour adjusts as dose changes, illustrating that the animal 
utilises control over responding to regulate total drug intake. Thus, it is less likely that 
physiologically irrelevant doses will be administered, as has been suggested for studies 
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Fig. 1.1 Dose	  response	  curve	  for	  MDMA	  self-­‐administration.	  Adapted	  from	  Schenk	  et	  
al.	  (2003).	  
Secondly, self-administered drug produces neuroadaptations that are not solely 
due to the action of the drug. For example, self-administered cocaine produced 
significantly greater changes in dopamine transporter binding than the same doses 
administered non-contingently, suggesting that the stimulus-response associations 
learned in self-administration contribute to the neuroadaptations produced by drugs of 
abuse (Miguéns et al., 2008). Because human users also have control over their drug 
intake, and because the neuroadaptations produced by drugs may be dependent on this 
control, self-administered MDMA is probably a better model of human drug 
administration than experimenter-administered MDMA. 
A third strength of the self-administration paradigm, and of particular relevance 
to MDMA, is that the overall pattern of drug taking is similar in animals and humans. 
On their first exposure to MDMA human users generally consume ½ - 1 ecstasy tablet 
(D. Hansen et al., 2001) with drug use being intermittent, but with experience some 
users may consume upwards of 20 pills in a session (Parrott, 2005; Verheyden et al., 
2003). A similar pattern of low, intermittent initial intake followed by increased intake 
in some subjects is seen in MDMA self-administration in rats and monkeys (Banks et 
al., 2008; Beardsley, Balster, & Harris, 1986; De La Garza et al., 2007; Schenk, 
Colussi-Mas, Do, & Bird, 2012). It is important that, in both animals and humans, 





exposure to MDMA was neuroprotective against the neuroadaptations produced by 
subsequent high dose administrations (Bhide, Lipton, Cunningham, Yamamoto, & 
Gudelsky, 2009; Piper, Ali, Daniels, & Meyer, 2010). Indeed, self-administered 
MDMA produced smaller deficits in tissue levels of 5-HT compared to high dose 
experimenter-administered MDMA (Do & Schenk, 2011; Scanzello, Hatzidimitriou, 
Martello, Katz, & Ricaurte, 1993; Schenk et al., 2007), even though the total amount 
self-administered (165-350 mg/kg over 20-30 days of testing) was greater than is 
generally administered to produce extensive neurotoxicity (20-80 mg/kg in a single 
day).  Given that the neuroadaptations produced by MDMA are dependent on the 
pattern of prior MDMA exposure, self-administered MDMA likely produces 
neuroadaptations more similar to the human condition than those produced by 
experimenter-administration. 
 Furthermore, the self-administration paradigm allows for the behaviour of drug 
taking to be studied, which can be useful when investigating how a certain 
manipulation might affect drug taking behaviour. In this manner, self-administration 
has been a valuable pre-clinical tool in determining the efficacy of purported 
treatments for reducing drug consumption. For example, self-administration of a range 
of drugs is reduced by vaccines that use the body’s immune system to block drugs 
from crossing the blood/brain barrier (Fox et al., 1996; Kantak, 2003; Skolnick, 2015). 
Based in part on the results of self-administration studies, a number of these vaccines 
have progressed to clinical trials, representing an exciting new potential rehabilitative 
tool for reducing drug taking (Heidbreder & Hagan, 2005; Skolnick, 2015). 
 Overall, the self-administration model allows for direct assessment of drug 
taking behaviour, and reduces some of the confounds associated with investigating the 
effects of experimenter-administered MDMA on animals (De La Garza et al., 2007; 
Fantegrossi, 2007). Furthermore, self-administration of MDMA produces different 
neuroadaptations to experimenter administration, and these neuroadaptations are 
probably more similar to those produced by regular recreational ecstasy use.  
Profile of MDMA self-administration 
Just as humans show tremendous variability in their patterns of ecstasy use, 
there is considerable variability in the self-administration of MDMA in animals. More 
specifically, some individuals are more vulnerable to the reinforcing effects of 





exposure. To investigate this variability our laboratory has defined an acquisition 
criterion and measured latency to acquisition of MDMA self-administration. To meet 
the acquisition criterion a rat must self-administer a total of 90 infusions of MDMA 
(1.0 mg/kg/infusion) within 25 self-administration sessions. Our laboratory has shown 
that roughly 50% of subjects will acquire MDMA self-administration under these 
conditions (Colussi-Mas, Wise, Howard, & Schenk, 2010; Schenk et al., 2012; Schenk 
et al., 2003; Schenk et al., 2007). Figure 1.2 presents raw data collected for this thesis 
that help to illustrate the variability in acquisition of MDMA self-administration. The 
top panel shows the number of MDMA infusions self-administered within the 25 
session for a subject (Kererū) that did not meet acquisition criteria. Responding across 
the 25 sessions is consistently low, although up to 3 infusions were self-administered 
within a session. It should be noted that this rate of self-administration is lower than 
that supported by the saline vehicle, which supports roughly 5-7 infusions per session. 
The middle panel shows the same data for a subject (Black Stilt) that was slow to 
acquire (24 sessions), while the bottom panel shows a subject (Kea) that acquired 
relatively quickly (13 sessions). As is typical in these self-administration studies, 
initial intake is low in all 3 subjects, but the subjects that did acquire show a sudden 
increase in intake. That Kea required less self-administration experience before 
increasing intake than Black Stilt shows the underlying variability in the reinforcing 
effects of MDMA between these subjects, and this variability is reflected in their 
latency to acquisition. The decrease in Kea’s responding in session 7 is typical after 
the first exposure to a high dose of MDMA, and can be seen to a lesser extent in the 
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Fig. 1.2 Number	  of	  MDMA	  infusions	  (1.0	  mg/kg/infusion)	  self-­‐administered	  over	  a	  25	  
day	  acquisition	  period.	  Top	  panel:	  a	  subject	  that	  did	  not	  acquire.	  Middle	  panel:	  A	  
subject	  that	  was	  slow	  to	  acquire	  (24	  sessions).	  Bottom	  panel:	  A	  subject	  that	  was	  
relatively	  quick	  to	  acquire	  (13	  sessions).	  
	  
 Of the subjects that do acquire MDMA self-administration, some self-
administer more reliably than others. In our laboratory once a subject meets the 
acquisition criterion the dose of MDMA is halved, and we expect that responding will 
compensate accordingly. Often, we will further increase the FR schedule so that more 
responses are required to obtain an infusion of drug. Some subjects will not increase 
responding as the FR schedule is increased, while in others responding will 
compensate for increases in FR (see Chapter 7). Figure 1.3 illustrates these 
compensatory increases in responding with data collected for this thesis from a rat that 
shows reliable self-administration. The top panel shows that responding compensated 
for the decrease in dose (from section A to section B), and for increases in FR values 
(sections C and D). The bottom panel shows that total intake becomes consistent over 
time, although initially there is some variability, particularly after the first high dose of 
MDMA was self-administered. 
    These patterns of self-administration behaviour have been a focus of our 
laboratory for some time. In particular, we find it interesting that some subjects will 
increase responding for MDMA after relatively low MDMA intake, while others will 
show similar behaviour after relatively high MDMA intake, and others still will not 
increase responding for MDMA within our 25 day cut-off period. We have suggested 
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Fig. 1.3 Top	  panel:	  lever	  presses	  reinforced	  by	  MDMA	  per	  session	  across	  different	  
MDMA	  doses	  and	  FR	  schedules.	  Section	  A:	  1.0	  mg/kg/infusion,	  FR	  1.	  Section	  B:	  0.5	  
mg/kg/infusion,	  FR	  1.	  Section	  C:	  0.5	  mg/kg/infusion,	  FR	  2.	  Section	  D,	  0.5	  
mg/kg/infusion,	  FR	  5.	  















Pharmacodynamics of MDMA 
MDMA has a diverse pharmacodynamic profile. Battaglia, Brooks, 
Kulsakdinun, and De Souza (1988) categorised the 5-HT transporter, 5-HT2 receptors, 
α2 adrenergic receptors, and M-1 muscarinic receptors as targets for which MDMA 
has high affinity (0-10µM). Moderate affinity (10µM-100µM) targets included the 
norepinephrine and dopamine transporters, and 5-HT1 receptors, and low affinity 
(>100µM) targets included dopamine-D1 and -D2 receptors and the choline 
transporter. A small number of studies have shown that MDMA produces modest 
increases in extracellular levels of glutamate (Anneken & Gudelsky, 2012; Nash & 
Yamamoto, 1992) and acetylcholine (Acquas et al., 2001; Nair & Gudelsky, 2006a, 
2006b), but there is limited evidence for effects on extracellular norepinephrine (Starr, 
Page, & Waterhouse, 2012) or GABA (Bankson & Yamamoto, 2004; Yamamoto, 
Nash, & Gudelsky, 1995). In contrast, a great deal of research on MDMA has focused 
on 5-HT and dopamine mechanisms.  
MDMA preferentially releases 5-HT via reverse transport (Gu & Azmitia, 
1993; Gudelsky & Nash, 1996; Hekmatpanah & Peroutka, 1990). Although MDMA 
has moderate affinity for the norepinephrine and dopamine transporters, MDMA is 
more potent at releasing 5-HT (EC50=74.3 nM) than norepinephrine (EC50=136 nM) or 
dopamine (EC50=278 nM) (Baumann, Wang, & Rothman, 2007). MDMA also inhibits 
the 5-HT transporter (Berger, Gu, & Azmitia, 1992; Rothman & Baumann, 2003), 
vesicular monoamine transporter 2 (Bogen, Haug, Myhre, & Fonnum, 2003; Erickson, 
Schafer, Bonner, Eiden, & Weihe, 1996; Pifl, Reither, & Hornykiewicz, 2015) and 
activity of monoamine oxidase A and B (Leonardi & Azmitia, 1994; Matsumoto et al., 
2014; Scorza et al., 1997). Thus, MDMA enhances extracellular 5-HT levels by 
inhibiting the reuptake of 5-HT, directly releasing 5-HT from terminals, inhibiting the 
packaging of 5-HT into vesicles, and inhibiting the degradation of 5-HT. Results from 
in vivo microdialysis studies reliably show that MDMA preferentially increases 
extracellular 5-HT levels (For review see Schenk (2011)). Following acute 
administration of MDMA there was an immediate (15 min) and prolonged (2 week) 
decrease in tryptophan hydroxylase activity, as measured by a 14CO2-trapping 
procedure (Schmidt & Taylor, 1987; Stone, Hanson, & Gibb, 1987; Stone, Johnson, 
Hanson, & Gibb, 1988; Stone, Merchant, Hanson, & Gibb, 1987), indicating that 





MDMA produces minor and transient reductions in dopamine transporter 
function, as  measured in ex vivo synaptosomes, but failed to alter dopamine 
transporter binding or tyrosine hydroxylase activity in rats (J. P. Hansen et al., 2002; 
Stone, Merchant, et al., 1987). Nonetheless, MDMA administration increases 
extracellular dopamine levels, as determined by in vivo microdialysis (for review, see 
Schenk (2011)). This increase is more modest than the MDMA-produced increase in 
extracellular 5-HT levels. For example, there was a 300% increase in extracellular 
dopamine concentrations in the nucleus accumbens following 3 mg/kg MDMA, but an 
1800% increase in extracellular 5-HT concentrations (Baumann, Clark, & Rothman, 
2008).  
A focus on 5-HT 
A question remains as to which of these effects of MDMA might be related to 
its self-administration. A wealth of data indicate that the reinforcing efficacy of a drug 
is directly related to its ability to increase synaptic levels of dopamine. For example, 
dopamine agonists reduced self-administration in a manner consistent with a leftward 
shift in the dose-response curve (Gardner, 2000; Yokel & Wise, 1978), suggesting 
enhanced reinforcement. On the other hand, dopamine antagonists produced 
responding consistent with a rightward shift in the dose-response curve (de Wit & 
Wise, 1977; Ettenberg, Pettit, Bloom, & Koob, 1982; Gardner, 2000; Yokel & Wise, 
1975), suggesting a decrease in reinforcement. Similarly, neurotoxic, 6-OH-DA, 
lesions also reduced the reinforcing efficacy of drugs of abuse (Gardner, 2000; Lyness, 
Friedle, & Moore, 1979; Roberts, Corcoran, & Fibiger, 1977; Roberts & Koob, 1982).  
As is true with other drugs of abuse, the reinforcing efficacy of MDMA, and 
thus the self-administration of MDMA, results from dopamine release. As indicated 
above, however, MDMA preferentially increases 5-HT, an effect that is incompatible 
with self-administration. For example, stimulation of 5-HT release inhibited (Rothman 
et al., 2005), while neurotoxic 5,7-DHT lesions enhanced (Bradbury et al., 2014; Loh 
& Roberts, 1990) self-administration. Self-administration of amphetamine-type drugs 
was inversely related to affinity for the 5-HT transporter (Ritz & Kuhar, 1989), or 
potency to stimulate 5-HT release (Wee et al., 2005). With specific reference to 
MDMA, the (+) isomer that selectively releases dopamine was more readily self-
administered than the (-) isomer that selectively releases 5-HT (Z. Wang & 





administration in general, and to MDMA self-administration in particular. Thus, 
MDMA-produced 5-HT release would be expected to inhibit MDMA self-
administration, yet, as outlined above, some rats will eventually self-administer 
MDMA reliably. It is possible that some rats are less responsive to these 5-HTergic 
effects and so self-administer MDMA more readily.   
 This hypothesis was recently directly tested in our laboratory. Firstly, the 5-
HTergic response to an initial dose of MDMA was determined by in vivo microdialysis 
before MDMA self-administration began. 5-HT release produced by this initial 
exposure to MDMA was lower in the rats that did acquire MDMA self-administration 
than in those that did not, while dopamine release was similar for both groups. 
Secondly, the effect of a neurotoxic 5,7-DHT lesion on acquisition of MDMA self-
administration was determined. The lesion reduced 5-HT tissue levels by up to 67%. 
Of interest, 100% of the lesion group acquired MDMA self-administration, compared 
to approximately 50% of controls, and the latency to acquisition was greatly reduced in 
the lesion group (Bradbury et al., 2014). Thus, lower 5-HT release produced by 
MDMA, either endogenous or exogenously produced by a lesion, was associated with 
enhanced self-administration. These findings support the hypothesis that MDMA-
produced 5-HT release is inhibitory to the acquisition of MDMA self-administration, 
but a question remains as to the mechanism for this inhibitory effect.   
It has been suggested that the development of MDMA as an efficacious 
reinforcer in the self-administration paradigm is due to neuroadaptations that occur in 
response to regular MDMA exposure, and that the same neuroadaptations could 
underlie the development of ecstasy SUDs (Schenk, 2011; Schenk & Aronsen, 2015). 
Microdialysis studies have shown that the 5-HTergic response to MDMA is attenuated 
after repeated exposure (Baumann, Clark, Franken, Rutter, & Rothman, 2008; 
Reveron, Maier, & Duvauchelle, 2010; Shankaran & Gudelsky, 1999), an effect that 
would be expected to facilitate MDMA self-administration. It has been hypothesised 
that this reduced 5-HTergic response to MDMA disinhibits the dopaminergic response, 
enhancing the reinforcing efficacy of MDMA and making it comparable to other drugs 
of abuse (Schenk, 2011). Furthermore, neuroadaptations in 5-HT receptors, as a result 
of MDMA exposure, have been suggested to enhance problematic behaviours, like 
impulsivity, that are associated with SUDs (Schenk & Aronsen, 2015).  
 Thus, repeated exposure to MDMA reduces the 5-HTergic response to MDMA, 





problematic drug taking. If the reinforcing effects of MDMA rely on 5-HTergic 
deficits, the variability in acquisition of MDMA self-administration might be due to 
increased vulnerability to MDMA-produced 5-HTergic neuroadaptations in some rats. 
Because 5-HTergic deficits enhance MDMA self-administration via a disinhibition of 
dopamine, there are likely specific 5-HT receptors that modulate the dopaminergic 
response to, and thus the self-administration of, MDMA.  
There are 14 different 5-HT receptor subtypes, arranged into 7 receptor 
families, and spread widely throughout the brain (Hoyer et al., 1994). The 5-HT1A and 
5-HT1B receptor subtypes have a role in the regulation of dopamine and the 
dopaminergic response to drugs of abuse, and as such changes in the activation of 
these receptor subtypes might be expected to alter the reinforcing effects of MDMA. 
5-HT1A and 5-HT1B receptors 
The 5-HT1A receptor is a seven transmembrane receptor that couples to Gi/Go 
to inhibit adenylyl cyclase and produce hyperpolarisation (Hamon et al., 1990; Innis, 
Nestler, & Aghajanian, 1988; Schoeffter & Hoyer, 1988). In the brain the 5-HT1A 
receptor is located both pre- and post-synaptically. Pre-synaptically, the 5-HT1A 
receptor is an autoreceptor on 5-HT neurons in the dorsal and median raphe nuclei, 
where activation inhibits 5-HT synthesis, and release of 5-HT in terminal regions 
(Hamon et al., 1988; Riad et al., 2000; Yoshimoto & McBride, 1992). 5-HT1A 
receptors have also been localised to the hippocampus, amygdala, prefrontal cortex 
(PFC), and the ventral tegmental area (VTA) where they act as heteroreceptors on 
dopamine, glutamate, and GABA cells (Doherty & Pickel, 2001; Hajós, Gartside, 
Varga, & Sharp, 2003; Hume et al., 2001; Maeda et al., 2001; Palchaudhuri & Flügge, 
2005; Pompeiano, Palacios, & Mengod, 1992; Puig, Artigas, & Celada, 2005; Puig, 
Watakabe, Ushimaru, Yamamori, & Kawaguchi, 2010). 
The 5-HT1B receptor is also a seven transmembrane protein that couples to 
Gi/Go to inhibit adenylyl cyclase and produce hyperpolarisation (Hartig, Branchek, & 
Weinshank, 1992; Hoyer & Middlemiss, 1989; Sari, 2004; Seuwen, Magnaldo, & 
Pouysségur, 1988; C. Wang et al., 2013). In the brain the 5-HT1B receptor is located 
pre-synaptically on the terminals of 5-HTergic or non-5-HTergic cells, as auto- or 
heteroreceptors, respectively (Boulenguez et al., 1996; Offord, Ordway, & Frazer, 
1988; Sari et al., 1999; Vergé et al., 1986). 5-HT1B receptor binding was high in globus 





hippocampus (Bonaventure, Schotte, Cras, & Leysen, 1997; Lindhe et al., 2011). 5-
HT1B mRNA was also abundant in the hypothalamus, thalamus, and amygdala 
(Bonaventure et al., 1998). As well as being present on 5-HTergic neurons, 5-HT1B 
receptors have been localised to dopaminergic (Sarhan & Fillion, 1999), GABAergic 
(Darrow, Strahlendorf, & Strahlendorf, 1990), and glutamatergic (Raiteri, Maura, 
Bonanno, & Pittaluga, 1986) terminals.  
Changes in 5-HT1A and 5-HT1B receptor protein levels, mRNA levels, or 
binding to G proteins, have been shown in response to general interventions such as 
exercise (Chennaoui et al., 2001; Fuss et al., 2013), stress  (Iyo et al., 2009; S. Wang, 
Zhang, Guo, Teng, & Chen, 2009), and steroid administration (Ambar & Chiavegatto, 
2009; Kindlundh, Lindblom, Bergström, & Nyberg, 2003). More importantly, changes 
have also been shown after repeated exposure to 5-HTergic ligands. 5-HT1A 
autoreceptors were down-regulated by chronic exposure to selective 5-HT reuptake 
inhibitors (SSRIs) (Castro, Diaz, del Olmo, & Pazos, 2003; Le Poul et al., 2000), 
although no changes in 5-HT1A autoreceptors were detected after repeated exposure to 
MDMA (Schenk, Abraham, Aronsen, Colussi-Mas, & Do, 2013). Chronic SSRI 
treatment also increased post-synaptic 5-HT1A receptor agonist-stimulated binding of 
[35S]GTPγS to G proteins (Castro et al., 2003; Moulin-Sallanon et al., 2009). Similarly, 
up-regulation of post-synaptic 5-HT1B receptors has been suggested as a result of 
repeated SSRI treatment (Le Poul et al., 2000). These findings suggest that the large 
increases in synaptic 5-HT produced by MDMA could also produce changes in these 
receptor subtypes. 
The role of 5-HT1A and 5-HT1B receptors in dopamine modulation 
The most commonly used 5-HT1A receptor agonist, 8-hydroxy-2-
dipropylaminotetralin (8-OH-DPAT), has high affinity for 5-HT1A receptors (Peroutka, 
1986). Low doses of 8-OH-DPAT preferentially activated 5-HT1A autoreceptors, while 
higher doses also activated heteroreceptors (Alex & Pehek, 2007; Hjorth & 
Magnusson, 1988). Low doses of 8-OH-DPAT simulated dopamine cell activity in the 
VTA (Gronier, 2008) and increased extracellular dopamine concentrations in the PFC 
(Arborelius, Nomikos, Hacksell, & Svensson, 1993) and VTA (Chen & Reith, 1995). 
Thus, activation of 5-HT1A autoreceptors enhances dopamine cell activity and 
extracellular dopamine concentrations. 
Higher doses of 8-OH-DPAT inhibited dopamine cell firing in the VTA 





nucleus accumbens (NAc) (Ichikawa & Meltzer, 2000) and striatum (Rasmusson, 
Goldstein, Deutch, Bunney, & Roth, 1994), as measured by in vivo microdialysis. The 
relatively new 5-HT1A receptor agonists, F13640, and F15599, both have >1000 fold 
selectivity for the 5-HT1A receptor  (Colpaert et al., 2002; Newman-Tancredi et al., 
2009), while the slightly older BAY × 3702 has approximately 30 fold selectivity for 
the 5-HT1A receptor (De Vry et al., 1998). Each of these agonists, when administered 
locally in the PFC, dose-dependently increased extracellular dopamine levels in the 
PFC (Díaz-Mataix, Artigas, & Celada, 2006; Díaz-Mataix et al., 2005; Lladó-Pelfort, 
Assié, Newman-Tancredi, Artigas, & Celada, 2012; Lladó-­‐Pelfort, Assié, Newman-­‐
Tancredi, Artigas, & Celada, 2010). It was suggested that this effect was due to 
inhibition of PFC GABA and glutamate cells, since endogenous 5-HT release inhibited 
electrophysiological recordings from PFC glutamate and GABA cells, and this effect 
was attenuated by a 5-HT1A receptor antagonist (Hajós et al., 2003; Puig et al., 2005; 
Puig et al., 2010; Sakaue et al., 2000). Thus, the effect of 5-HT1A receptor activation 
on dopamine release is region specific – activation of autoreceptors, or heteroreceptors 
in the PFC, increased extracellular dopamine concentrations, while global activation of 
heteroreceptors decreased extracellular dopamine concentrations in the NAc and 
striatum.   
 There is evidence that activation of 5-HT1A receptors is inhibitory to the 
dopaminergic response to drugs of abuse. The 5-HT1A receptor agonist, 8-OH-DPAT, 
inhibited amphetamine-induced dopamine release in the PFC (Kuroki, Ichikawa, Dai, 
& Meltzer, 1996), striatum and NAc (Ichikawa, Kuroki, Kitchen, & Meltzer, 1995) as 
determined by microdialysis. 5-HT1A receptor agonists generally inhibited the 
hyperactive response to amphetamine, methamphetamine, and MDMA (Müller, Carey, 
Huston, & Silva, 2007), a response that has been associated with enhanced dopamine 
neurotransmission (Wise & Bozarth, 1987). Furthermore, the expression and 
development of cocaine or amphetamine sensitisation in mice was inhibited by 5-HT1A 
receptor agonist administration (Ago et al., 2006; Przegaliñski, Siwanowicz, Baran, & 
Filip, 2000). Thus, increased activation of 5-HT1A receptors during MDMA self-
administration might be expected to inhibit the dopaminergic response to MDMA. 
In vitro studies showed that activation of 5-HT1B receptors inhibited the release 
of dopamine (Sarhan & Fillion, 1999), GABA (Johnson, Mercuri, & North, 1992; Yan 
& Yan, 2001b), and glutamate (Muramatsu, Lapiz, Tanaka, & Grenhoff, 1998), but 





the most widely used 5-HT1B receptor agonists, RU 24969 (5-Methoxy-3-(1,2,5,6-
tetrahydro-4-pyridinyl)-1H-indole), has high affinity for 5-HT1B receptors (Ki = 0.38 
nM), but also displays appreciable affinity for the 5-HT1A receptor (Ki = 2.5 nM) 
(Peroutka, 1986; Wolf & Kuhn, 1991). Systemic administration of RU 24969 
decreased extracellular GABA concentrations in the VTA in vivo, but had no effect on 
extracellular dopamine concentrations (Parsons, Koob, & Weiss, 1999). However, 
local administration of the 5-HT1B receptor agonist, CP 93129, which has 150 fold 
selectivity for 5-HT1B over other 5-HT receptors (Macor et al., 1990), increased 
extracellular dopamine concentrations in the PFC (Iyer & Bradberry, 1996), striatum 
(Galloway, Suchowski, Keegan, & Hjorth, 1993), and NAc (Hållbus, Magnusson, & 
Magnusson, 1997; Yan & Yan, 2001a). Similarly, administration of CP 93129 in the 
VTA increased extracellular dopamine levels in the NAc (O'Dell & Parsons, 2004; 
Yan & Yan, 2001a; Yan, Zheng, & Yan, 2004) and decreased extracellular GABA 
concentrations in the VTA (O'Dell & Parsons, 2004; Yan et al., 2004), without altering 
extracellular glutamate concentrations in the VTA (O'Dell & Parsons, 2004). Together 
these findings suggest that activation of 5-HT1B receptors enhances dopamine release, 
possibly via an inhibition of GABA neurotransmission. 
There is evidence that activation of 5-HT1B receptors enhances the 
dopaminergic response to drugs of abuse. Cocaine produced significantly greater 
increases in extracellular dopamine, and significantly greater reductions in 
extracellular GABA, in the NAc after systemic administration of the 5-HT1B/1A 
receptor agonist, RU 24969 (Parsons et al., 1999). A similar response to cocaine was 
found after infusion of the 5-HT1B receptor agonist, CP 93129, in the VTA (O'Dell & 
Parsons, 2004). Systemic administration of the 5-HT1B receptor agonist, CP 94253, 
which has approximately 45 fold selectivity for 5-HT1B over other 5-HT receptors 
(Koe, Nielsen, Macor, & Heym, 1992), significantly prolonged the increase in 
extracellular dopamine in the NAc produced by systemic administration of ethanol 
(Yan, Zheng, Feng, & Yan, 2005). 5-HT1B receptor agonists produced a leftward shift 
in the cocaine self-administration dose response curve, increased the break points 
achieved in cocaine progressive ratio tasks (Parsons, Weiss, & Koob, 1998; 
Pentkowski, Acosta, Browning, Hamilton, & Neisewander, 2009; Przegaliñski, Gołda, 
Frankowska, Zaniewska, & Filip, 2007), and produced a leftward shift in the self-
administration dose response curve for the dopamine uptake inhibitor, GBR 12909 





MDMA self-administration might be expected to enhance the dopaminergic response 
to MDMA.  
Thus, 5-HT1A and 5-HT1B receptors might be expected to impact the initial 
reinforcing effects of MDMA, via dopaminergic modulation. Specifically, activation 
of 5-HT1A receptors would be expected to decrease the dopaminergic response to 
MDMA, while activation of 5-HT1B receptors would be expected to enhance the 
dopaminergic response to MDMA. Furthermore, alterations in the activation of these 
receptors might explain the enhancement in the reinforcing efficacy of MDMA after 
repeated exposure. As outlined below, individual variability in these receptor 
populations, or MDMA-produced changes in these receptor populations, might also 
impact the reinforcing effects of MDMA and explain behavioural deficits seen in 
regular ecstasy users.  
 5-HT1A and 5-HT1B receptors and impulsivity 
Impulsivity has been broadly defined as action without foresight, referring to 
behaviours that are poorly thought out, prematurely executed, or risky (Winstanley, 
Eagle, & Robbins, 2006). In drug users impulsivity is a risk factor for initiating drug 
taking, escalating drug use, and for developing SUDs (De Wit, 2009; Perry & Carroll, 
2008). For example, impulsive traits in youth and young-adulthood positively 
predicted future drug use, an earlier onset of drug taking, and the likelihood of 
developing an SUD  (De Wit, 2009; Kirisci, Tarter, Mezzich, & Vanyukov, 2007; 
Sher, Bartholow, & Wood, 2000; Tarter, Kirisci, Feske, & Vanyukov, 2007).  
A role of impulsivity in different aspects of drug self-administration in animals 
has been determined. Some studies have looked at the acquisition and maintenance of 
self-administration, based on the idea that highly impulsive subjects, as is the case with 
humans, might be more prone to take drugs (Perry & Carroll, 2008). Typically, 
impulsivity is measured by a model of behavioural inhibition, such as the 5 choice 
serial reaction time task (5CSRTT), or a model of choice preference for a delayed 
reward, such as the delay discounting paradigm. These measures show good validity as 
they are variants of those used to assess aspects of impulsive behaviour in humans 
(Evenden, 1999b; Robbins, 2002). Delay discounting and reaction time tasks can be 
used to determine impulsivity scores across a group of animal subjects, which can then 
be divided into  ‘low impulsivity’ (LI) groups and ‘high impulsivity’ (HI) groups. HI 
subjects are usually defined as those in the upper quartile of impulsivity scores, with 





groups can then be compared to determine the relationship between impulsivity and 
drug self-administration.  
When impulsivity was determined using a delay discounting task HI rats 
consumed more ethanol (Poulos, Le, & Parker, 1995), or cocaine (Koffarnus & 
Woods, 2013; Perry, Larson, German, Madden, & Carroll, 2005; Perry, Nelson, & 
Carroll, 2008), and cocaine self-administration was acquired more quickly and in a 
higher percentage of HI rats (Perry et al., 2005; Zlebnik & Carroll, 2015). Similarly, 
HI rats, as measured by 5CSRTT performance, acquired nicotine self-administration 
more readily (Diergaarde et al., 2008), and a strain of mice with high impulsivity 
showed enhanced ethanol self-administration (Loos, Staal, Smit, De Vries, & Spijker, 
2013). Following acquisition, HI rats, as determined by the 5CSRTT, self-administered 
more cocaine per hour than LI rats, and exhibited an upward shift in the cocaine dose 
response curve (Dalley et al., 2007). Furthermore, impulsivity as determined by the 
5CSRTT predicted the magnitude of the drug-seeking response for MDMA in the 
reinstatement paradigm (Bird & Schenk, 2013). Thus, higher levels of impulsivity 
would be expected to facilitate self-administration. 
Systemic administration of the 5-HT1A receptor agonist, 8-OH-DPAT, 
increased premature responding on the 5CSRTT (Carli & Samanin, 2000) while the 5-
HT1A receptor antagonist, WAY 100635 (N-[2-[4-(2-methoxyphenyl)-1-
piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide), which has >100-fold 
selectivity for the 5-HT1A receptor over other receptors (A. Fletcher et al., 1995), 
supressed impulsive action in a 3CSRTT (Ohmura et al., 2013). The effects of 5-HT1A 
ligands on impulsivity appear to be due to autoreceptor activation, because neither 
local administration of 8-OH-DPAT in the PFC, nor systemic administration of the 5-
HT1A post-synaptic preferring receptor agonist F15599, affected premature responding 
on the 5CSRTT (Carli, Baviera, Invernizzi, & Balducci, 2006; Lladó-­‐Pelfort et al., 
2010; Winstanley et al., 2003). 
In humans, 5-HT1B receptor gene polymorphisms are associated with impulsive 
aggression (Zouk et al., 2007). Mice that lack the 5-HT1B receptor gene from birth 
show increased impulsivity in a behavioural model of response inhibition (Nautiyal et 
al., 2015; Pattij et al., 2003). Interestingly, knockdown of 5-HT1B autoreceptors did not 
affect impulsivity, suggesting the effect of 5-HT1B receptor activation on impulsivity is 
due to heteroreceptor action (Nautiyal et al., 2015). Studies of the effects of 5-HT1B 





behavioural effects that disrupt operant responding (Evenden, 1999a; van den Bergh, 
Bloemarts, Groenink, Olivier, & Oosting, 2006). However, the limited available data 
suggest that activation of 5-HT1B receptors reduces impulsive behaviour (Evenden, 
1999a). Therefore, activation of 5-HT1B receptors during MDMA self-administration 
would be expected to reduce impulsive behaviour, and thus inhibit self-administration. 
5-HT1A and 5-HT1B receptors and learning 
Before reliable self-administration behaviour can be demonstrated, the subject 
must learn the association between performance of the operant response and the 
infusion of drug. Enhanced or inhibited ability to learn this association would clearly 
also enhance or inhibit the acquisition of self-administration. There is also another 
learned association that has been shown to be incredibly important in the self-
administration paradigm - the Pavlovian association between the drug effect and the 
contextual stimuli (e.g. the light). These unconditioned contextual stimuli develop 
conditioned reinforcement properties over repeated pairings with a drug (Ahrens, 
Singer, Fitzpatrick, Morrow, & Robinson, 2016; W. M. Davis & Smith, 1976; P. J. 
Fletcher & Korth, 1999b) and these conditioned reinforcers are a powerful driver of 
self-administration behaviour. For example, one experiment assessed the acquisition of 
nicotine self-administration in two groups of rats – one in which the nicotine infusion 
was paired with the illumination of a light, and another in which the infusion was 
paired with no specific cues. Rats in the nicotine + cue group took less time to show a 
preference for the active self-administration lever and consumed significantly more 
nicotine than the nicotine only group, suggesting the Pavlovian association between 
drug effect and contextual cues facilitated acquisition of self-administration (Caggiula 
et al., 2002). Therefore, enhanced or inhibited learning of either operant or Pavlovian 
associations would be expected to enhance or inhibit self-administration, respectively.  
 The strengthening of stimulus/reward associations is markedly impacted by 
pharmacological manipulation of 5-HT1A receptors. Systemic 5-HT1A receptor agonist 
administration impaired performance on an appetitive Pavlovian conditioned 
responding task (Blair, Bonardi, & Hall, 2004), increased errors in a repeated 
acquisition of response sequence task (Winsauer, Rodriguez, Cha, & Moerschbaecher, 
1999) and delayed acquisition of operant responding maintained by a food reinforcer 
(Frick, Bernardez-Vidal, Hocht, Zanutto, & Rapanelli, 2015). Furthermore, the 5-HT1A 
receptor agonist, 8-OH-DPAT, administered after an initial training session, impaired 





response functions in these studies limits the degree to which the relative roles of 5-
HT1A auto- and heteroreceptors can be disentangled. Importantly, the above results 
were noted over a range of 8-OH-DPAT doses that would be expected to activate pre- 
and post-synaptic 5-HT1A receptors (up to 1.0 mg/kg). When low doses of 8-OH-
DPAT were used, operant learning was enhanced (Meneses & Hong, 1994b), and this 
effect was reversed by the tryptophan hydroxylase inhibitor, pCPA (Meneses & Hong, 
1994a). Together, these results suggest that activation of 5-HT1A autoreceptors 
enhances, while activation of 5-HT1A heteroreceptors inhibits, learning of 
stimulus/reward associations.  
The non-selective 5-HT receptor agonist, mCPP, inhibited operant 
stimulus/response learning, and this effect was reversed by the non-selective 5-HT1B 
receptor antagonist, propranolol (Meneses & Hong, 1997). Moreover, the 5-HT1B 
receptor agonist, CGS 12066 impaired (Meneses, 2007), while  the 5-HT1B/1D receptor 
antagonist, GR 127935, improved (Meneses, Terrón, & Hong, 1997) performance on 
the same task. Similarly, the 5-HT reuptake facilitator, tianeptine, enhanced operant 
stimulus/response learning, and this effect was reversed by the 5-HT1B receptor inverse 
agonist, SB 224289 (Meneses, 2002). These findings suggest that activation of 5-HT1B 
receptors inhibits the consolidation of operant learning, and so activation of 5-HT1B 
receptors during MDMA self-administration might be expected to inhibit the 
development of self-administration. 
5-HT1A and 5-HT1B receptors and anxiety 
Anxiety disorders are frequently comorbid with SUDs (Ipser, Wilson, 
Akindipe, Sager, & Stein, 2015; Merikangas et al., 1998). It has been suggested that 
anxiety may underlie the initiation of drug taking, in order to alleviate a negative 
emotional state, and negatively reinforce the continuation of drug use to mitigate 
withdrawal symptoms (Altman et al., 1996; Belin, Belin-­‐Rauscent, Everitt, & Dalley, 
2015; Lejuez et al., 2008). In animal models, anxiety is often operationalised in 
rodents as an aversion to open or brightly lit spaces (Belin et al., 2015). A popular 
method for measuring anxiety is the elevated plus maze (EPM), in which a preference 
for the closed (protected) arms of the maze over the open arms is regarded as an 
‘anxious’ response (Pellow, Chopin, File, & Briley, 1985). An alternate measure of 
rodent anxiety is self-grooming behaviour in response to an environmental change 
(Homberg et al., 2002). Rats in the upper quartile for time spent grooming in a novel 





administration than the lower quartile group (Homberg et al., 2002). This effect was 
not replicated when high anxiety was determined by performance on the EPM, 
however in this case high and low anxiety were determined using a median split, thus 
possibly masking an effect of anxiety (Bush & Vaccarino, 2007). Higher anxiety on 
the EPM was associated with escalation of cocaine self-administration (Dilleen et al., 
2012), and propensity to self-administer alcohol (Spanagel et al., 1995). Thus, higher 
levels of anxiety would be expected to facilitate self-administration.  
Time spent in the open arms of the EPM was increased by systemic 
administration of low doses of the 5-HT1A receptor agonist, 8-OH-DPAT (Kwieciński 
& Nowak, 2009; Lalonde & Strazielle, 2010), an effect reversed by the 5-HT1A 
receptor antagonist, WAY 100635 (Collinson & Dawson, 1997), suggesting 5-HT1A 
autoreceptor activation had an anxiolytic effect. Higher doses of systemically 
administered 8-OH-DPAT had an anxiogenic effect in the same task in mice (Miheau 
& Van Marrewijk, 1999).When injected into the dorsal or median raphe, 8-OH-DPAT 
increased time spent in the open arms of the EPM (De Almeida, Giovenardi, Charchat, 
& Lucion, 1998; File & Gonzalez, 1996; File, Gonzalez, & Andrews, 1996), while 
injections into the hippocampus (Cheeta, Kenny, & File, 2000a; File et al., 1996; File, 
Kenny, & Cheeta, 2000), PFC (Solati, Salari, & Bakhtiari, 2011), or  septum (Cheeta, 
Kenny, & File, 2000b; De Almeida et al., 1998) increased anxiety-like behaviour in 
the EPM. Thus, activation of 5-HT1A autoreceptors had anxiolytic effects in the EPM, 
while activation of post-synaptic 5-HT1A receptors was anxiogenic.  
 Early investigations of the role of 5-HT1B receptors in anxiety states found that 
non-selective 5-HT1B receptor agonists decreased time spent in the open arms of an 
EPM (Benjamin, Lal, & Meyerson, 1990; Critchley & Handley, 1987; Pellow, 
Johnston, & File, 1987), suggesting that activation of 5-HT1B receptors was 
anxiogenic. The role of 5-HT1B receptors in modulating anxiety was more recently 
confirmed; entries into the open arms of the EPM were dose-dependently reduced by 
the 5-HT1B receptor agonist CP 94253, and this effect was reversed by the 5-HT1B/1D 
receptor antagonist, GR 127935 (Lin & Parsons, 2002). The relative contribution of 5-
HT1B auto- and heteroreceptors to this effect is not clear.  5-HT1B heteroreceptors on 
GABAergic amygdala neurons have been suggested as a possible neuronal mechanism 
(Lin & Parsons, 2002; Sari, 2004) because 5-HT1B manipulations of these projections 
altered behaviour in the EPM (Audi, De Oliveira, & Graeff, 1991). Furthermore, 





(Solati et al., 2011) however, a role of 5-HT1B autoreceptors cannot be ruled out (Sari, 
2004). 
Summary 
 MDMA is widely used recreationally in the form of the street drug, ecstasy. 
Although the majority of users consume ecstasy intermittently, there is concern that 
MDMA produces a range of deficits in regular ecstasy users. Among these deficits, 
ecstasy users show increased anxiety and impulsivity, and impaired learning and 
memory. Problematically, these behavioural changes might be expected to facilitate 
further ecstasy taking.  
MDMA is unique among drugs of abuse in that it primarily acts as a 5-HT 
releasing agent. 5-HT release has been hypothesised to inhibit the self-administration 
of drugs in general, and of MDMA in particular. Nonetheless, MDMA self-
administration is acquired in roughly 50% of animal subjects. It is possible that 
MDMA-produced 5-HT release inhibits the reinforcing efficacy of MDMA via 
activation of specific 5-HT receptors, but there is likely variability in the 5-HTergic 
response to MDMA between individuals. Furthermore, it is possible that 
neuroadaptations in 5-HT receptors underlie both the facilitated reinforcement 
produced by MDMA after repeated exposure, and the cognitive and behavioural 
deficits seen after regular use.  
 The 5-HT1A and 5-HT1B receptors are good candidates for these effects of 
MDMA. Both receptors modulate the reinforcing effects of other drugs of abuse by 
regulating dopamine release. Furthermore, these receptors mediate a number of 
behaviours associated with self-administration that are impacted by regular ecstasy 
use, and receptor up- or down-regulation has been documented in response to a 
number of different interventions.  
This thesis will explore two ways in which alterations in 5-HT1A and/or 5-HT1B 
receptors could influence MDMA self-administration. Firstly, underlying differences 
in 5-HT1A and/or 5-HT1B receptors could predispose some subjects to self-administer 
more readily. This may explain the variability in acquisition of MDMA self-
administration. If so, it is hypothesised that manipulations that alter 5-HT1A and/or 5-






 Secondly, MDMA exposure during self-administration might produce changes 
in these receptor populations that might facilitate further drug taking and produce 
behavioural deficits. If so, it is hypothesised that these changes will be evident after 
substantial MDMA self-administration. Theoretically, if these changes are not the 
result of neurotoxicity, they could be partially reversed by repeated administration of 







Male Sprague-Dawley rats were bred in the Victoria University of Wellington 
vivarium. They were housed in groups of 4 in a temperature- (19-21ºC) and humidity- 
(55%) controlled environment until they reached weights of 300-350g, after which 
they were housed individually. The housing colony was maintained on a 12 h 
light/dark cycle (lights on at 7.00 am) and all tests were conducted during the light 
portion of the cycle. Food and water were freely available except during testing. 
Drugs 
 RU 24969 hemisuccinate, WAY 100635 maleate, lithium chloride, ±8-OH-
DPAT hydrobromide, (Tocris, New Zealand), and d-amphetamine sulfate (BDG, New 
Zealand) were dissolved in sterilised saline. GR 127935 hydrochloride (Tocris, New 
Zealand) was dissolved in distilled water. All injections were a volume of 1.0 ml/kg. 
±MDMA hydrochloride (BDG, New Zealand) for self-administration was dissolved in 
sterilised saline containing 3IU heparin per ml. 
All doses refer to salt weights.  
Apparatus and procedures 
Water consumption 
Water consumption was measured in the home cage. Water bottles were 
removed for 24 hours. Drug administration occurred before water bottles were 
reintroduced, at times specified in each study. Consumption was measured for a 30 
minute period. Fluid consumption was determined by weighing water bottles before 
and after the test.  
Locomotor Activity 
 Locomotor activity testing was conducted in clear Plexiglas chambers (Med 
Associates Inc., USA; model ENV-515) measuring 42×42×30 cm, set in sound-
attenuating boxes. Forward locomotion was measured with two sets of 16 infrared 
beams and sensors spaced evenly along the sides of the chambers producing squares 
measuring 25mm × 25mm. The interruption of three adjacent beams (the approximate 
size of the body of a rat) was recorded as one activity count. A white noise generator 
was used during experiments to mask any outside noise, and chambers were washed 
with Virkon ‘S’ disinfectant (Southern Veterinary Supplies, NZ) after testing to control 





that was used to illuminate the room during drug administrations. Locomotor activity 
counts were recorded in 5 minute intervals. 
Surgery 
For rats that underwent self-administration testing, a silastic catheter was 
implanted into the right jugular vein under deep anesthesia produced by i.p. injection 
of ketamine (90 mg/kg) and xylazine (9 mg/kg). Areas surrounding skin that was to be 
cut were shaved and washed with ethanol and iodine, and eye lubricant (Refresh lacri-
lube) was administered to avoid drying. The catheter was secured in place using 
surgical string and a small amount of adhesive (Bostick superglue). The distal end of 
the catheter was passed subcutaneously to an exposed part of the skull, attached to a 3 
cm piece of 22 gauge stainless steel tubing (BD needles), fixed in place with screws 
and a small amount of adhesive, and embedded in dental acrylic (Ostron 100). The 
silastic tubing was coated with silicone (Selleys wet area silicone) to protect from the 
corrosive nature of the adhesive. Following surgery an analgesic (Carporfen ®, 5.0 
mg/kg, s.c.) and electrolyte replacement (Hartman’s solution, 12 ml, s.c.) were 
administered. Carprofen was also administered on each of two days following the 
surgery. Testing began once pre-surgery weight had been attained, generally within 4-
6 days. 
Self-administration 
 Every day, before self-administration testing, rats were weighed and 
administered penicillin dissolved in heparinised saline (0.2 ml, i.v.) to help maintain 
general health and catheter patency. 
Self-administration was conducted in operant chambers (Med Associates ENV-
001) equipped with two levers. Depression of the active lever resulted in a 12 second 
activation of a syringe pump (Razell, Model A, 1 RPM) resulting in a 0.1 ml 
intravenous infusion, and the simultaneous illumination of the house light located 
above the active lever. Depressions of the inactive lever were recorded, but had no 
programmed consequence. Each self-administration session began with an 
experimenter-delivered infusion to fill the volume of the catheter. These infusions are 






Chapter 3: Development of behavioural assays 
These first studies were designed to develop behavioural assays for 5-HT1A and 
5-HT1B receptor activation, so that further testing of the effects of drug exposure on the 
function of these receptor subtypes could be conducted. One assay that seemed 
promising was latent inhibition: the impairment of learning that a stimulus predicts an 
important event when that stimulus has previously been presented with no 
consequence (Cassaday, Hodges, & Gray, 1993).  
When a neutral stimulus, for example a tone, is paired with a negative 
consequence, for example a footshock, that stimulus will develop conditioned-stimulus 
properties and produce freezing behaviour in rodents. A group of rats that had never 
been exposed to the tone (control group) would learn this association relatively 
quickly. However, if the tone has previously been presented to another group of rats 
without consequence (pre-exposure group), learning that the tone now predicts a 
footshock will take longer in this group. Therefore, after a small number of pairings, 
the tone will produce less freezing behaviour in the pre-exposure group, because the 
association between the tone and the footshock is less well learned. Latent inhibition 
can be operationalised as this behavioural difference (reduced freezing behaviour) 
between groups. Latent inhibition is a robust effect, found across a range of stimulus-
consequence combinations in a wide range of species (Fernández, Giurfa, Devaud, & 
Farina, 2012; Ferrari & Chivers, 2011; Lubow, 1989). 
A number of studies have implicated 5-HT in latent inhibition. Electrolytic, or 
neurotoxic 5,7 DHT, lesions of the median raphe or NAc blocked the latent inhibition 
effect (Loskutova, 2001; Loskutova, Luk'yanenko, & Il'yuchenok, 1990; Solomon, 
Nichols, Kiernan, Kamer, & Kaplan, 1980). Rats in the pre-exposure group showed 
greater 5-HT metabolism in the striatum and amygdala than rats in the control group, 
suggesting the latent inhibition effect is associated with increased 5-HTergic activity 
(Molodtsova, 2003). Additionally, rats with a genetic deletion of the 5-HT transporter 
showed reduced latent inhibition compared to wildtype counterparts (Nonkes et al., 
2012).  
The role of 5-HT in latent inhibition is reinforced by studies employing 
selective pharmacological ligands. The 5-HT1B/1A receptor agonist, RU 24969 (0.5 
mg/kg), administered before each pre-exposure, inhibited the development of latent 
inhibition, while the more selective 5-HT1A receptor agonist, 8-OH-DPAT, had no 





latent inhibition. On the other hand, the 5-HT1A receptor antagonist, WAY 100635 (0.5 
mg/kg), facilitated latent inhibition in the same task (Killcross, Stanhope, Dourish, & 
Piras, 1997), suggesting 5-HT1A receptors also impact the expression of latent 
inhibition. Thus, RU 24969 inhibited the development of latent inhibition, but the 
relative roles of 5-HT1A and 5-HT1B receptor activation in this effect, and the range of 
doses over which this effect is produced, have not been determined. 
 The majority of studies have employed a footshock when investigating latent 
inhibition. Given the well-established role of 5-HT, and particularly 5-HT1A receptors, 
in the processing of pain (Avila-Rojas et al., 2015; Colpaert, 2006; Colpaert et al., 
2002; Panczyk et al., 2015), I wanted an alternative paradigm to test for latent 
inhibition. Latent inhibition can be readily demonstrated using the conditioned taste 
aversion paradigm. Conditioned taste aversion refers to the phenomenon whereby an 
unfamiliar taste (e.g. a new blend of coffee), paired with a negative internal state (e.g. 
feeling sick after drinking), results in future avoidance of that taste (the new coffee). 
This association is rapidly learned if the taste stimulus is novel, but this learning is 
hampered if the taste stimulus has previously not predicted the illness (e.g. your usual 
coffee blend). Thus, prior exposure to the neutral stimulus, without negative 
consequence, inhibits the learning of an association, and so latent inhibition can be 
demonstrated through an attenuated conditioned taste aversion. In rats this is typically 
achieved by pairing flavoured water with a drug (e.g. lithium chloride) that produces 
“internal malaise” (Lubow, 1989, p. 5). One pairing of the flavoured water with the 
drug is sufficient to ensure the animal avoids the flavoured water in the future, but this 
effect is attenuated if, previously, the flavoured water has been consumed without 
consequence (Ellenbroek, Knobbout, & Cools, 1997; Mora et al., 1999). This 
paradigm has been successfully used to investigate the effects of antipsychotic-type 
drugs on latent inhibition (Geyer & Ellenbroek, 2003; Moser, Hitchcock, Lister, & 
Moran, 2000). 
 As a first attempt to assess the roles of 5-HT1A and 5-HT1B receptors in latent 
inhibition, the effect of the 5-HT1B/1A receptor agonist, RU 24969, on latent inhibition 







 Firstly, I aimed to establish the conditioned taste aversion effect, based on the 
methods of Ellenbroek et al. (1997). All testing was conducted in the home cages. 
Water bottles were removed from the home cages and made available for 30 minutes 
per day. Rats (see general methods, n=8 per group) were randomly assigned to have 
either water (water pre-exposure group) or a 5% sucrose solution (sucrose pre-
exposure group) available for drinking. Water bottles were weighed before and after 
each 30 minute drinking period to measure consumption. Once total consumption 
during this pre-exposure phase reached 40ml (approximately 3 days; Ellenbroek et al. 
(1997)), rats in both groups received the 5% sucrose solution for 30 minutes. 
Immediately after this 30 minute drinking period, lithium chloride (75 mg/kg, i.p.; 
Ellenbroek et al. (1997)) was administered. The next day both water and the sucrose 
solution were made available for 30 minutes. Taste aversion was measured as the 
proportion of sucrose consumed on this test day (amount of sucrose solution consumed 
divided by total fluid consumption), with lower proportions of sucrose consumption 
indicative of greater taste aversion. Thus, latent inhibition was indicated by a lower 
taste aversion (i.e. greater proportion of sucrose consumption) in the sucrose pre-
exposure group. 
Other groups were tested to determine the effect of RU 24969 pretreatment on 
this latent inhibition effect. The same protocol were used, but 15 minutes prior to water 
bottles being available during the pre-exposure phase, rats were injected with RU 
24969 (0, 0.03, 0.3, 3.0 mg/kg, s.c.). This range of RU 24969 doses has been shown to 
be behaviourally effective in different paradigms (Kennett, Dourish, & Curzon, 1987; 
Tricklebank, Middlemiss, & Neill, 1986). The 15 minute RU 24969 pretreatment time 
is common (Acosta, Boynton, Kirschner, & Neisewander, 2005; P. J. Fletcher & 
Korth, 1999b), because maximal effects have been shown between 15 minutes and 4 
hours after administration (Tricklebank et al., 1986). 
Statistical analyses 
 Fluid consumption was compared as a function of pre-exposure using one-way 
analysis of variance (ANOVA). A 3 (RU 24969 dose) × 3 (Session) mixed model 
ANOVA, with session as the within subjects factor, was used to analyse the effect of 
RU 24969 on fluid consumption as a function of pre-exposure session. Where 






Experiment 1: Pilot study on the Conditioned Taste Aversion effect 
Rats in both pre-exposure groups (n=8 per group) met the fluid consumption 
criterion in 3 daily pre-exposure sessions. There was no difference in total fluid 
consumption between the sucrose and water groups (F(1,14)=2.10, p=0.17). Figure 3.1 
shows the water pre-exposure group demonstrated conditioned taste aversion, as 
indicated by the low proportion of sucrose consumed on the test day. The sucrose pre-
exposure group showed significantly greater sucrose consumption than the water pre-
exposure group (F(1,14)=4.53, p=0.05, ɳp2= 0.25). Figure 3.1 shows that the sucrose 
pre-exposure group consumed similar amounts of water and sucrose on the test day, 
suggesting the internal malaise produced by lithium chloride was not associated with 
the sucrose solution, thus illustrating latent inhibition.   























Fig. 3.1 Conditioned	  taste	  aversion	  to	  sucrose	  after	  pairing	  with	  lithium	  chloride	  in	  
rats	  either	  pre-­‐exposed	  to	  sucrose	  or	  water.	  The	  lack	  of	  preference	  for	  water	  over	  
sucrose	  in	  the	  sucrose	  pre-­‐exposure	  group	  is	  indicative	  of	  latent	  inhibition.	  n	  =	  8	  per	  
group,	  error	  bars	  represent	  SEM.	  *p=0.05	  
 
Experiment 2: The effect of RU 24969 on Conditioned Taste Aversion 
Only 11 subjects were available at the beginning of this experiment, so they 
were divided into groups that received different doses of RU 24969 (0.0, 0.03, 0.3, 3.0 
mg/kg, s.c.) and different pre-exposures (water, sucrose; n=2-3 per group) with the 





the initial groups treated with RU 24969 appeared to consume less fluid in the daily 30 
minute sessions. Figure 3.2 shows the fluid consumption over the first 3 sessions 
(collapsed across pre-exposure group) as a function of RU 24969 dose. It is clear that 
higher RU 24969 dose groups initially consumed less fluid than the lower dose groups. 
ANOVA confirmed a significant effect of RU 24969 dose (F(3,54)=25.8, p<0.001, 
ɳp2=0.59), and a post-hoc Tukey test showed that the 3.0 and 0.3 mg/kg RU 24969 
dose groups both consumed less fluid than the 0.0 and 0.03 mg/kg groups across the 
first 3 sessions. This decrease in fluid consumption provided a confound that would 
compromise interpretation of a conditioned taste aversion experiment. Therefore, no 
further testing was conducted. 
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Fig 3.2 The	  effect	  of	  RU	  24969	  dose	  on	  the	  amount	  of	  fluid	  consumed	  by	  fluid-­‐
deprived	  rats	  during	  the	  first	  3	  drinking	  sessions.	  RU	  24969	  dose-­‐dependently	  
decreased	  fluid	  consumption,	  with	  the	  0.3	  and	  3.0	  mg/kg	  groups	  consuming	  
significantly	  less	  fluid	  over	  the	  3	  sessions.	  n=4-­‐6	  per	  group,	  error	  bars	  represent	  SEM.	  
Discussion 
 The latent inhibition effect was successfully produced using the conditioned 
taste aversion paradigm. However, the impact of RU 24969 on this effect could not be 
assessed because higher doses of RU 24969 reduced fluid consumption. These results 
showed that the conditioned taste aversion paradigm was a confounded assay for 
measuring behavioural responses to RU 24969 under these conditions.  
Serendipitously, the results also suggested a more straightforward measure of 





been alluded to in the literature. For example, RU 24969 non-selectively reduced 
intake of both water and sweetened ethanol (Silvestre, Palacios, Fernandez, & O'Neill, 
1998), responding maintained by water in water-deprived rats (Carli, Invernizzi, 
Cervo, & Samanin, 1988), and the time spent drinking sweetened condensed milk 
(Simansky & Vaidya, 1990). To our knowledge there had not been any 
pharmacological studies to determine whether this decrease in fluid consumption is 
due to effects at 5-HT1A or 5-HT1B receptors. In many ways the adipsic response to RU 
24969 would be a preferable behavioural response to measure, because only one drug 
exposure is required, and because the effect can be assessed in a relatively short time 
period. Thus, the next study aimed to determine the parameters of RU 24969-produced 







Chapter 4: Behavioural responses to RU 24969 
Parts of this chapter appear in:  
Aronsen, Webster, & Schenk. (2014). RU 24969-produced adipsia and 
hyperlocomotion: Differential role of 5-HT1A and 5-HT1B receptor 
mechanisms. Pharmacology, Biochemistry and Behavior, 124, 1-4. DOI 
10.1016/j.pbb.2014.05.008 
Aronsen, Bukholt, & Schenk (2016). Repeated administration of the 5-HT1B/1A agonist, 
RU 24969, facilitates the acquisition of MDMA self-administration: Role of 5-
HT1A and 5-HT1B receptor mechanisms. Psychopharmacology, 233 (8), 1339-
1347. DOI 10.1007/s00213-016-4225-x 
 
 The previous chapter showed that latent inhibition, assessed using the 
conditioned taste aversion paradigm, is a confounded behavioural assay due to 
decreased fluid consumption produced by RU 24969. This decrease in fluid 
consumption might, however, be a novel response that could be used to characterise 
RU 24969. This effect had been referred to in the literature, but no study had 
determined the parameters of this adipsic response to RU 24969, or the contribution of 
5-HT1A and 5-HT1B receptors. This was, therefore, one objective of this study.  
RU 24969 also produces hyperlocomotion. In contrast to RU 24969-produced 
adipsia, this behavioural response to RU 24969 has been well studied. RU 24969-
produced hyperactivity was not attenuated by depletion of brain 5-HT, suggesting a 
post synaptic mechanism (Cheetham & Heal, 1993). Studies in mice have generally 
attributed RU 24969-induced hyperlocomotion to 5-HT1B mechanisms because it was 
selectively attenuated by pretreatment with 5-HT1B, but not 5-HT1A, receptor 
antagonists (Cheetham & Heal, 1993; Shanahan et al., 2009). In the rat, however, there 
is a lack of full parametric analysis of the roles of 5-HT1A or 5-HT1B activation in this 
behavioural response. For example, the 5-HT1B/1D receptor antagonist, GR 127935, 
dose-dependently attenuated the hyperactive response to RU 24969 in  the Wistar-
Kyoto hyperactive rat, but a control strain was not assessed (Chaouloff, Courvoisier, 
Moisan, & Mormede, 1999). Similarly, GR 127935 blocked the hyperactive response 
to RU 24969 50-60 minutes after RU 24969 administration (O’Neill & Parameswaran, 
1997), while the 5-HT1A receptor antagonists, WAY 100635 and SDX 216-525, but 
not GR 127935, blocked the hyperactive response to RU 24969 in the first 15 minutes 





evident. Thus, roles of 5-HT1A and 5-HT1B receptors in RU 24969-produced 
hyperlocomotion have been suggested, but the relative contribution of 5-HT1A and 5-
HT1B receptors over the course of RU 24969-produced hyperactivity is not clear.  
These studies had 3 aims. Firstly, the adipsic and hyperactive responses to RU 
24969 were characterised by administering a range of doses and measuring dose-
dependent behavioural responses. Secondly, the relative contributions of 5-HT1A and 
5-HT1B receptors to these effects were determined by pretreating rats with a selective 
5-HT1A or 5-HT1B receptor antagonist. Lastly, if a behavioural response to RU 24969 
was antagonised by a 5-HT1A receptor antagonist the same response was to be tested 
after administration of the selective 5-HT1A receptor agonist, 8-OH-DPAT. A more 
selective, well characterised, 5-HT1B receptor agonist was not readily available to us at 
the time of these experiments, but 8-OH-DPAT has been widely used as a selective 5-
HT1A receptor agonist. 8-OH-DPAT has approximately 7000 fold preference for 5-
HT1A receptors over 5-HT1B receptors (Hamon, Cossery, Spampinato, & Gozlan, 
1986). Therefore, 8-OH-DPAT is a preferable ligand to use when measuring 
behavioural responses to 5-HT1A receptor activation. 
Method 
Water consumption 
Standard protocol was used (see General Methods). RU 24969 (0.0 – 3.0 
mg/kg, s.c.; n = 10 per group) was administered 15 minutes before water bottles were 
reintroduced. These data provided the dose of RU 24969 that was subsequently used in 
the antagonist study. Separate groups (n=6-9 per group) were tested in the same 
manner to assess the contribution of 5-HT1A or 5-HT1B mechanisms. Either the 5-HT1A 
receptor antagonist, WAY 100635 (0.0, 1.0 mg/kg, s.c.), or the 5-HT1B/1D receptor 
antagonist, GR 127935 (0.0, 3.0 mg/kg, s.c.) was administered 15 minutes before RU 
24969 (1.0 mg/kg, s.c.). These doses were chosen for their documented efficacy in 
blocking 5-HT1A and 5-HT1B effects, respectively (Acosta et al., 2005; P. J. Fletcher & 
Korth, 1999b). 
Locomotor Activity 
Rats were placed in the testing chamber for 30 minutes, followed by an 
injection of RU 24969 (0.0-3.0 mg/kg, s.c.; n=8 per group), and activity was measured 
for 45 minutes post-injection. Separate groups (n=6-12 per group) were placed in the 





1.0 mg/kg, s.c.) or GR 127935 (0.0, 3.0 mg/kg, s.c.), followed 15 minutes later by RU 
24969 (3.0 mg/kg, s.c.). In order for the data to be directly comparable to the fluid 
consumption protocol, only data collected from 15-45 minutes following the injection 
of RU 24969 were analysed. 
 Separate rats were used to test the hyperactive response to 8-OH-DPAT. Rats 
were placed in the testing chamber for 30 minutes, followed by an injection of 8-OH-
DPAT (0.0, 0.03, 0.1, 0.3, 1.0, 3.0 mg/kg, s.c., n=5-7 per group), and activity was 
measured for 60 minutes post-injection.  
8-OH-DPAT is a selective 5-HT1A receptor agonist but also has appreciable 
affinity for 5-HT7 receptors (Bard et al., 1993; Lovenberg et al., 1993). To determine 
whether 8-OH-DAT-produced hyperactivity was due to 5-HT1A activation we 
determined the effect of the selective 5-HT1A receptor antagonist, WAY 100635, on 8-
OH-DPAT-produced hyperactivity. Rats were placed in the testing chamber and 15 
minutes later were injected with WAY 100635 (0, 0.003, 0.3 mg/kg, s.c., n=4-5 per 
group). Following a further 15 minutes, 8-OH-DPAT (0.3 mg/kg, s.c.) was injected, 
and activity was measured for an additional 60 minutes.  
 
Data analysis 
The effect of RU 24969 on water consumption was assessed using a one-way 
ANOVA. The effect of RU 24969 on locomotor activity was assessed using a 4 (RU 
24969 dose) × 6 (Time after injection) mixed ANOVA with Time as the within 
subjects factor. The effects of WAY 100635 and GR 127935 on RU 24969-proudced 
adipsia or hyperlocomotion were assessed using separate 2 (antagonist dose) × 2 (RU 
24969 dose) ANOVAs. The effect of 8-OH-DPAT on locomotor activity counts was 
assessed using a one-way ANOVA. Data for 8-OH-DPAT-produced hyperactivity 
after administration of WAY 100635 were analysed using a 3 (Dose) × 12 (Time after 
injection) mixed model ANOVA with Time as the within subjects factor. Post-hoc 





























Fig. 4.1 Effect	  of	  RU	  24969	  on	  water	  consumption	  over	  30	  minutes	  in	  water	  deprived	  
rats.	  n=	  10	  per	  group,	  error	  bars	  represent	  SEM.	  *-­‐	  p<0.05	  compared	  to	  0.0	  mg/kg	  
dose. 
Figure 4.1 shows the effect of RU 24969 on water consumption. ANOVA 
confirmed an effect of dose (F (4, 45) = 24.56, p<0.001, ɳp2= 0.69), and post hoc 
Tukey analysis indicated that 0.3, 1.0, and 3.0 mg/kg RU 24969 significantly 
decreased water consumption (p<0.05). Effects of the antagonists on RU 24969-










Fig. 4.2 Effect	  of	  the	  5-­‐HT1B/1D	  receptor antagonist,	  GR	  127935	  (left),	  or	  the	  5-­‐HT1A	  
receptor	  antagonist,	  WAY	  100635	  (right),	  on	  RU	  24969-­‐produced	  adipsia.	  n=6-­‐9	  per	  

































































Analysis of the effect of WAY 100635 (dose RU 24969 × dose WAY 100635) 
revealed a main effect of RU 24969 (F (1,26) = 26.95, p<.001, ɳp2= 0.51), but no effect 
of WAY 100635 (F (1,26) = 0.016, ns) or an interaction (F (1,26) = 0.83, ns). In 
contrast, analysis of the effect of GR 127935 (dose RU 24969 × dose GR 127935) 
revealed an effect of GR 127935 (F (1,24) = 4.55, p=0.043, ɳp2= 0.16), an effect of RU 
24969 (F (1,24) = 29.44, p<0.001 ɳp2= 0.55) and an interaction (F (1,24) = 9.02, p = 
0.006 ɳp2= 0.27). Tukey post hoc comparisons confirmed that GR 127935 significantly 
reduced RU 24969-produced adipsia (p<0.05). 
Figure 4.3 shows that RU 24969 increased locomotor activity (F (3,28) = 8.15, 
p<0.001 ɳp2= 0.47). There was no effect of Time (F (5,140) = 0.27, ns) and no 
interaction (F (15,140) = 0.45, ns). Post hoc Tukey analysis showed the dose of 3.0 










Fig. 4.3 Effect	  of	  RU	  24969	  on	  locomotor	  activity.	  n=8	  per	  group,	  error	  bars	  represent	  
SEM.	  *-­‐	  p<0.05.	  
 
Effects of the antagonists on RU 24969-produced hyperlocomotion are 
presented in figure 4.4. GR 127935 failed to alter RU 24969-produced hyperactivity; 
the effect of GR 127935 (F (1,26) = 0.75, ns) and the interaction (F (1,26) = 0.52, ns) 
between the two drugs were not significant. A significant effect of WAY 100635 was 
found (F (1,36) = 6.73, p = 0.014, ɳp2= 0.16), and an interaction between WAY 
100635 and RU 24969 treatment was significant (F (1,36) = 4.44, p = 0.042, ɳp2= 
0.11). Tukey post hoc comparisons confirmed that WAY 100635 significantly reduced 
RU 24969-produced hyperactivity (p<0.05).  
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Fig. 4.4 Effect	  of	  the	  5-­‐HT1B/1D	  receptor	  antagonist,	  GR	  127935	  (left),	  or	  the	  5-­‐HT1A	  
receptor	  antagonist,	  WAY	  100635	  (right),	  on	  RU	  24969-­‐produced	  hyperactivity.	  n=6-­‐
12	  per	  group,	  error	  bars	  represent	  SEM.	  *-­‐	  p<0.05.	  
 
8-OH-DPAT dose-dependently increased locomotor activity counts 
(F(5,33)=48.63, p<0.001, ɳp2= 0.88). Post hoc analysis revealed that doses of 0.3, 1.0, 
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Fig. 4.5 The	  hyperactive	  response	  to	  8-­‐OH-­‐DPAT.	  n=5-­‐7	  per	  group,	  error	  bars	  
represent	  SEM.	  *-­‐	  p<0.05	  compared	  to	  0.0	  mg/kg	  group.	  
 
Figure 4.6 (left panel) shows the time course of the effects of WAY 100635 on 
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between Time after injection and Dose (F(22,121)=7.66, p<0.001, ɳp2= 0.58), and 
significant main effects of Time (F(11,121)=31.1, p<0.001, ɳp2= 0.74) and Dose 
(F(2,11)=21.5, p<0.001, ɳp2= 0.80). Post hoc tests revealed a significant decrease in 8-
OH-DPAT-produced hyperactivity at Time=5, 10 and 15 minutes following 
administration of 0.3 mg/kg WAY 100635. The effect of dose is further illustrated in 
Figure 4.6 (right panel). Post hoc analysis showed a significant decrease in 8-OH-
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Fig. 4.6 (left	  panel)	  Time	  course	  of	  8-­‐OH-­‐DPAT-­‐	  (0.3	  mg/kg)	  produced	  locomotor	  
activity	  following	  WAY	  100635.	  (right	  panel)	  Effects	  of	  WAY	  100635	  on	  total	  
locomotor	  activity	  following	  administration	  of	  8-­‐OH-­‐DPAT	  (0.3	  mg/kg).	  n	  =	  5-­‐6	  per	  




The 5-HT1B/1A receptor agonist, RU 24969, dose dependently decreased water 
consumption and increased locomotor activity. The different potencies of RU 24969 in 
the two behavioural paradigms were consistent with the differential affinity of RU 
24969 for the 5-HT1A and 5-HT1B receptors; RU 24969 has about 6 times greater 
affinity for the 5-HT1B receptor subtype than the 5-HT1A receptor subtype (Peroutka, 
1986). In the behavioural tasks, the lowest dose of RU 24969 that affected fluid 
consumption was 0.3 mg/kg, while RU 24969-induced hyperlocomotion was only 
observed after 3.0 mg/kg. 
The most convincing evidence of different receptor mechanisms for RU 24969-
induced adipsia and hyperlocomotion is that a dose of the 5-HT1B/1D receptor 





hyperlocomotion effect of RU 24969. Further, a dose of the 5-HT1A receptor 
antagonist, WAY 100635, which blocked the locomotor activating effects failed to 
alter the adipsic response to RU 24969. The failure of these doses of WAY 100635 and 
GR 127935 to alter one behaviour cannot be due to ineffective dosing since the other 
behavioural effect of RU 24969 was attenuated by the same dose of the antagonist. It 
might be argued that the decrease in drinking reflects the hyperactive response to RU 
24969 that might have interfered with the ability to remain at the drinking spout. This 
is unlikely since the reduction of fluid consumption was produced by doses of RU 
24969 lower than those that increased locomotor activity.  
Rather, the data are consistent with the idea that RU 24969-induced adipsia in 
rats is mediated by 5-HT1B, but not 5-HT1A, mechanisms, and that RU 24969-induced 
hyperactivity in rats is mediated by 5-HT1A, but not 5-HT1B, mechanisms. Another 
study (Chaouloff et al., 1999) showed that GR 127935 attenuated RU 24969-induced 
hyperactivity in Wistar-Kyoto hyperactive  rats. This effect might have been non-
selective since GR 127935 in that study also decreased basal activity levels. We failed 
to observe either of these effects in Sprague-Dawley rats, raising the possibility that 
there are strain differences in the response to the antagonist. Another study (O’Neill & 
Parameswaran, 1997) also showed that  RU 24969-induced hyperactivity was 
decreased by GR 127935, but this effect was produced 50-60 minutes after RU 24969 
administration. This finding raises the possibility that there is an effect of GR 127935 
that emerges at time points later than those tested in the present study. In accordance 
with our conclusion that RU 24969-induced hyperlocomotion is due to this agonist’s 
affinity for the 5-HT1A receptor, 5-HT1A receptor agonists are known to produce 
hyperlocomotion (Kalkman & Soar, 1990; Tricklebank, Forler, & Fozard, 1984).   
GR 127935 has affinity for a number of serotonin receptors (Centurión et al., 
2000; Price et al., 1997; Watson, Burton, Price, Jones, & Middlemiss, 1996), but it is 
noteworthy that the 5-HT1B/1D receptor antagonist is at least 60 times more selective 
for the 5-HT1B receptor than any of the other receptors that RU 24969 has notable 
affinity for. Therefore, the most likely explanation for the reversal of RU 24969-
induced adipsia by GR 127935 is antagonism of the 5-HT1B receptor.  
These results, along with others from the literature, raised the possibility that a 
5-HT1A receptor agonist would also produce reliable hyperlocomotion. Given the high 
selectivity of 8-OH-DPAT for the 5-HT1A receptor, as well as the low affinity for the 





hyperactivity would be a preferable behavioural measure of 5-HT1A activation. Thus, 
the last study in this chapter aimed to determine the parameters under which 8-OH-
DPAT produces hyperactivity, and the role of 5-HT1A receptor activation in this effect.  
8-OH-DPAT dose dependently increased locomotor activity, with a maximal 
effect around 1.0 mg/kg. This hyperactive response to the 5-HT1A receptor agonist was 
reversed by the 5-HT1A receptor antagonist, WAY 100635. It is unlikely that this 
reversal by WAY 100635 was due to a non-specific decrease in locomotor activity 
because the higher (1.0 mg/kg) dose of WAY 100635 used in the previous experiment 
had no significant effect on locomotor activity. Therefore, these results suggest that 8-
OH-DPAT-produced hyperactivity is due to 5-HT1A receptor activation.  
This result is in accordance with other studies that have investigated the 
hyperlocomotor response to 8-OH-DPAT. Hyperactivity produced by 8-OH-DPAT 
was attenuated by the 5-HT1 receptor antagonist, pindolol (Ahlenius & Salmi, 1995; 
Hillegaart, Estival, & Ahlenius, 1996), suggesting a 5-HT1A receptor mechanism. 8-
OH-DPAT produced hyperlocomotion was not attenuated by depletion of monoamines 
via reserpine treatment, suggesting this behavioural response to 8-OH-DPAT is not 
due to alterations in synthesis and/or release of 5-HT via autoreceptor-mediated 
effects, but instead action on post-synaptic 5-HT1A receptors (Ahlenius & Salmi, 1995; 
Mignon & Wolf, 2002).  
Together, these data show that adipsia and hyperlocomotion provide 
dissociable behavioural measures of RU 24969 that are produced by 5-HT1B and 5-
HT1A activation, respectively. Furthermore, 8-OH-DPAT-produced hyperactivity may 
be a preferable measure of 5-HT1A activation, because of the selectivity of 8-OH-
DPAT for the 5-HT1A receptor. Because RU 24969-produced adipsia and 8-OH-
DPAT-produced hyperactivity are selective responses to 5-HT1B and 5-HT1A receptor 
activation, respectively, these procedures provide straight-forward assays of 5-HT1A 






Chapter 5: Effects of repeated administration of the 5-HT1B/1A receptor agonist, 
RU 24969, on the acquisition of MDMA self-administration 
Parts of this chapter appear in:  
Aronsen, Bukholt, & Schenk (2016). Repeated administration of the 5-HT1B/1A agonist, 
RU 24969, facilitates the acquisition of MDMA self-administration: Role of 5-
HT1A and 5-HT1B receptor mechanisms. Psychopharmacology, 233 (8), 1339-
1347. DOI 10.1007/s00213-016-4225-x 
 
As was explained in the General Introduction, self-administration of a range of 
substances is inhibited by increased synaptic 5-HT (Loh & Roberts, 1990; Ritz & 
Kuhar, 1989; Rothman et al., 2005; Z. Wang & Woolverton, 2007; Wee et al., 2005). 
A recent study (Bradbury et al., 2014) tested the idea that MDMA-produced 5-HT 
release might be inhibitory to MDMA self-administration and attempted to explain 
both the long latency to acquisition, and the small proportion of rats that meet 
acquisition criteria. The MDMA-produced increase in synaptic 5-HT was measured by 
in vivo microdialysis before MDMA self-administration began. As has been observed 
in many studies from the Schenk lab (Colussi-Mas et al., 2010; Schenk et al., 2012; 
Schenk et al., 2003; Schenk et al., 2007), about 50% of the rats acquired MDMA self-
administration. Of interest, MDMA-stimulated 5-HT release was lower for the rats that 
ultimately met the acquisition criteria, suggesting an inhibitory role of MDMA-
produced 5-HT release on the acquisition of MDMA self-administration. This idea was 
experimentally tested by determining the effect of a neurotoxic, 5,7-DHT, lesion on 
MDMA self-administration. The lesion reduced 5-HT levels by up to 67%, and greatly 
facilitated the acquisition of MDMA self-administration; while approximately 50% of 
control rats met acquisition criteria, 100% of the lesion group acquired. Furthermore, 
of the control group that acquired, 50% met the criterion within 14 sessions, while only 
6 sessions were required for 50% of the lesion group to meet the criterion. 
These findings strengthen the idea that variability in the acquisition of MDMA 
self-administration is due to variability in sensitivity to MDMA-produced 5-HT 
release. Specifically, 5-HT has an inhibitory impact on MDMA self-administration. A 
question remains as to the mechanism for this inhibitory effect of 5-HT on the 
acquisition of MDMA self-administration. One possibility is that high levels of 





neuroadaptive changes in 5-HT receptor mechanisms that modulate responses 
associated with the acquisition of self-administration.  
As outlined in the General Introduction, 5-HT1A and 5-HT1B receptors regulate 
dopaminergic neurotransmission. Because self-administration is associated with 
increased dopamine neurotransmission, activation of 5-HT1A and 5-HT1B receptors 
might be expected to impact self-administration. Of particular interest, activation of 5-
HT1A receptors attenuated amphetamine-induced increases in extracellular dopamine 
levels (Ichikawa et al., 1995; Kuroki et al., 1996) and, as would therefore be expected, 
a range of 5-HT1A receptor agonists have been shown to inhibit self-administration 
(Müller et al., 2007). On the other hand, 5-HT1B receptor agonists potentiated the 
increase in extracellular dopamine produced by cocaine or ethanol (O'Dell & Parsons, 
2004; Parsons et al., 1999; Yan et al., 2005), and generally enhanced self-
administration, producing leftward shifts in the self-administration dose-response 
curves for cocaine and GBR 12909 (Parsons et al., 1996, 1998; Pentkowski et al., 
2009; Przegaliñski et al., 2007).  
A wealth of data indicate a role of 5-HT1A and 5-HT1B receptor subtypes in the 
maintenance of self-administration (P. J. Fletcher, Azampanah, & Korth, 2002; 
Neisewander, Cheung, & Pentkowski, 2014; Parsons et al., 1998; Peltier & Schenk, 
1993; Przegaliñski et al., 2007) but the role in the acquisition of self-administration has 
received far less attention. Given that self-administration is driven by increases in 
dopamine neurotransmission, and that the acquisition of MDMA self-administration 
was enhanced by a neurotoxic, 5,7-DHT lesion, I wanted to determine whether this 
facilitation of MDMA self-administration was due to decreased activation of 5-HT1A 
or 5-HT1B receptors. If so, it should be possible to manipulate receptor mechanisms via 
repeated agonist or antagonist exposure and to determine the effect on acquisition of 
MDMA self-administration. 
Tolerance to RU 24969-produced hyperactivity was produced following 
repeated exposure to the 5-HT1B/1A receptor agonist (Oberlander, Demassey, Verdu, 
Van de Velde, & Bardelay, 1987). As outlined in the previous chapter, we have 
recently shown that RU 24969-produced hyperactivity in rats is due to activation of 5-
HT1A, but not 5-HT1B, receptors (Aronsen, Webster, & Schenk, 2014), suggesting that 
behavioural tolerance reflects a down-regulation of this receptor subtype. The effect of 
RU 24969 pretreatment on 5-HT1B receptor mechanisms has not been specifically 





question (Aronsen et al., 2014). Therefore, in the present study we determined the 
effect of repeated exposure to RU 24969 on the acquisition of MDMA self-
administration, and on RU 24969-produced adipsia. In order to assess the effect on 5-
HT1A receptor mechanisms we also measured hyperactivity in response to the selective 
5-HT1A receptor agonist, 8-OH-DPAT.  
Method 
Male Sprague-Dawley rats (see General Methods) were used. For rats that 
underwent self-administration testing, an intravenous catheter was implanted, as 
outlined in the General Methods. 
RU 24969 pretreatment 
RU 24969 pretreatment began once pre-surgery weight had been obtained. RU 
24969 (3.0 mg/kg, s.c.), or the saline vehicle (1.0 ml/kg), was administered in the 
home cage daily at 0900hr and 1600hr, for three consecutive days. This protocol was 
adapted from that used in earlier studies (Callaway & Geyer, 1992; Oberlander et al., 
1987) to utilise a dose of RU 24969 that we have previously shown produces both 
hyperactivity and adipsia (Aronsen et al., 2014). 
Acquisition of MDMA self-administration 
Self-administration sessions began the day after the last administration of RU 
24969. Self-administration was conducted during 2 hour daily sessions, 6 days per 
week. Each self-administration session began with an experimenter-delivered infusion 
of drug to clear the line of heparinised saline solution. Thereafter, depression of the 
active lever produced an infusion of MDMA (1.0 mg/kg/infusion) according to an FR1 
schedule. Responses on the active and inactive levers were recorded. Every seventh 
day catheters were infused with sodium pentobarbital (20.0 mg/kg, i.v.). Failure to 
demonstrate an immediate loss of the righting reflex suggested a loss of catheter 
patency and the rat was excluded from the study. Catheter patency was lost in 4 rats (3 
RU 24969 pretreated, 1 saline pretreated), and 3 rats in the RU 24969 pretreatment 
group self-administered lethal doses of MDMA, resulting in final sample sizes of 9 and 
8 for the RU 24969 and saline pretreated groups, respectively. Self-administration 
testing continued for each rat until a total of 90 infusions (90.0 mg/kg) had been self-
administered, or for 25 days, whichever came first. This acquisition criterion is the 
same as has been used previously in our laboratory (Bradbury et al., 2014; Oakly, 





Water consumption and locomotor activity 
 Separate groups of rats were tested to determine the effects of RU 24969 
pretreatment on RU 24969-produced adipsia, or 8-OH-DPAT-produced hyperactivity. 
The standard water consumption protocol was used (see General Methods), with water 
bottles removed the day after the last RU 24969 pretreatment administration. RU 
24969 (0.0, 1.0, 3.0 mg/kg, s.c., n= 6-8 per group) was administered 15 minutes before 
water bottles were reintroduced. These doses were chosen based on our previous study 
(Aronsen et al., 2014) that suggested that adipsia following administration of these 
doses of RU 24969 was due to 5-HT1B receptor activation.  
The effect of the selective 5-HT1A receptor agonist, 8-OH-DPAT, on locomotor 
activity was assessed 2 days after the last administration of RU 24969, in order to 
match the delay between pretreatment and the test for RU 24969-induced adipsia. Rats 
were placed in the testing chamber (see General Methods) for 30 minutes, followed by 
an injection of 8-OH-DPAT (0.0, 0.1, 0.3 mg/kg, s.c., n=4-7 per group), and activity 
was measured for 60 minutes post-injection. 
To investigate the possibility that RU 24969 pretreatment affected 
dopaminergic mechanisms, locomotor activity produced by the dopamine releasing 
agent, d-amphetamine, was assessed 2 days after the last administration of RU 24969. 
Rats pretreated with either RU 24969, or vehicle, were placed in the testing chamber 
(see General Methods) for 30 minutes, followed by an injection of d-amphetamine (0.5 
mg/kg, i.p., n=10 per group), and activity was measured for 60 minutes post-injection. 
This dose was chosen because it has previously been used in our laboratory to illustrate 
dopaminergic sensitisation (Bradbury, Gittings, & Schenk, 2012). 
Data analysis 
Acquisition of self-administration was compared between pretreatment groups 
with a survival analysis, using the log-rank test to compare Kaplan-Meier survival 
estimates (Kaplan & Meier, 1958). Right-censoring was applied to data from rats that 
did not acquire within the 25 day cut-off period. 
RU 24969-produced adipsia was analysed with a 2 (Pretreatment) × 3 (Dose of 
RU 24969) ANOVA. Effects of each dose of 8-OH-DPAT on locomotor activity were 
analysed by individual 2 (Pretreatment) × 12 (Time after injection) mixed model 
ANOVAs with Time as the within subjects factor. Total activity counts as a function 
of Dose of 8-OH-DPAT and RU 24969 pretreatment were analysed using a 2 





amphetamine was analysed with a 2 (pretreatment) × 12 (Time after injection) mixed 
model ANOVA with Time as the within subjects factor.  
Results 
Figure 5.1 shows survival curves for the acquisition of self-administration for 
saline- or RU 24969-treated groups. RU 24969 pretreatment produced a significant 
increase in the probability of acquiring MDMA self-administration (χ² (1) = 12.21, 
p<0.01). Of the control group that met the acquisition criterion, 50% met the criterion 
within 17 sessions, whereas 50% of RU 24969 pretreatment group met the acquisition 
criterion within 10 sessions. It is noteworthy that three rats in the RU 24969 
pretreatment group self-administered lethal doses of MDMA (>20 mg/kg) during the 
first self-administration session and therefore additional data from these rats could not 
be obtained. The high intake during the first self-administration session for these 3 rats 
supports the other data suggesting RU 24969 pretreatment enhanced the initial 
reinforcing effects of MDMA. 
 
 

















Fig. 5.1 Cumulative	  percentage	  of	  rats	  that	  met	  the	  criterion	  for	  acquisition	  of	  MDMA	  
self-­‐administration	  in	  the	  RU	  24969	  (squares,	  n=9)	  and	  saline	  (circles,	  n=8)	  
pretreatment	  groups.	  
 
Figure 5.2 (left panel) shows the effect of RU 24969 pretreatment on RU 
24969-produced adipsia. There was a significant interaction between Pretreatment and 
Dose (F(2,37)=7.85, p=0.01, ɳp2= 0.30) and a significant effect of Dose 





the adipsic response between the RU 24969 and saline pretreatment groups following 
0.0 mg/kg, and 3.0 mg/kg RU 24969. Since there was a decrease in basal water 
consumption produced by repeated RU 24969 treatment, the data were further 
analysed by expressing drug effects as a percentage of baseline. These data are 
presented in Figure 5.2 (right panel). A 2×2 (Pretreatment × Dose) ANOVA revealed a 

























































Fig. 5.2 (Left	  panel)	  The	  adipsic	  response	  to	  RU	  24969	  after	  repeated	  exposure	  to	  RU	  
24969	  (grey	  bars)	  or	  saline	  (black	  bars).	  (Right	  panel)	  Percentage	  of	  baseline	  water	  
intake	  as	  a	  function	  of	  RU	  24969	  dose	  for	  RU	  24969	  and	  saline	  pretreated	  groups.	  
n=6-­‐8	  per	  group.	  Figures	  represent	  the	  mean	  +	  SEM.	  *	  -­‐	  p<0.05.	  
 
Locomotor activity produced by the various doses of 8-OH-DPAT as a 
function of RU 24969 pretreatment is shown in Figure 5.3. There were no differences 
between groups following the 0.0 mg/kg 8-OH-DPAT dose. The data from 0.1 mg/kg 
8-OH-DPAT dose produced a Time × Pretreatment interaction (F(11,110)=4.06, 
p<0.01, ɳp2= 0.29) and main effects of Time (F(11,110)=19.8, p<0.01, ɳp2= 0.66) and 
Pretreatment (F(1,10)=17.6, p<0.01, ɳp2= 0.64). Post hoc tests revealed significant 
decreases in activity during Time=10 and 15 minutes following the injection. There 
was a significant Time × Pretreatment interaction (F(11,121)=2.77, p<0.01, ɳp2= 0.20) 
and main effects of Time (F(11,121)=62.5, p<0.01, ɳp2= 0.85) and Pretreatment 
(F(1,11)=7.45, p<0.05, ɳp2= 0.40) for the 0.3 mg/kg 8-OH-DPAT groups. Post-hoc 
tests revealed a significant decrease in activity at Time=25 minutes. Analysis of total 





DPAT Dose (F(2,27)=46.0, p<0.01, ɳp2= 0.77) and a main effect of Pretreatment 
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Fig 5.3. Locomotor	  activating	  effects	  of	  8-­‐OH-­‐DPAT	  (Top	  left	  –	  0	  mg/kg,	  top	  right	  –	  
0.1	  mg/kg,	  bottom	  left	  –	  0.3	  mg/kg,	  bottom	  right	  –	  totals)	  as	  a	  function	  of	  RU	  24969	  
or	  saline	  pretreatment.	  n	  =	  4-­‐7	  per	  group.	  Symbols	  represent	  the	  mean	  +	  SEM.	  *-­‐	  
p<0.05.	  
 
During testing of the hyperactive response to d-amphetamine, one rat in the RU 
24969 pretreatment group jumped out of the locomotor activity chamber during 
testing, and so was excluded from analyses. The final sample size for this group was 
therefore 9. Figure 5.4 (left panel) shows the locomotor response to d-amphetamine for 
both pretreatment groups over time. ANOVA showed no significant effect of 
Pretreatment (F(1,17)=0.19, p=0.67) and no interaction between Pretreatment and 
Time (F(11,187)=0.29, p=0.99). Total locomotor activity counts after d-amphetamine 
injection are shown in figure 5.4 (right panel). As indicated in the previous analysis of 
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Fig. 5.4 The	  locomotor	  response	  to	  d-­‐amphetamine	  (0.5	  mg/kg)	  after	  pretreatment	  
with	  either	  RU	  24969	  or	  saline.	  n=9-­‐10	  per	  group.	  
Discussion 
Pretreatment with RU 24969 decreased the latency to acquisition of MDMA 
self-administration, and increased the proportion of rats that acquired MDMA self-
administration. The leftward shift in the acquisition curve for self-administration might 
reflect a sensitised reinforcing effect since higher doses of drug have also been shown 
to decrease the latency to acquisition of self-administration (Carroll & Lac, 1997; 
Schenk & Partridge, 2000).  
A remarkable consequence of pretreatment with RU 24969 was the substantial 
increase in the proportion of rats that met the criterion for acquisition of MDMA self-
administration. As we have previously reported (Bradbury et al., 2014; Schenk et al., 
2012), 50% of control rats met the criterion within the 25 day cut-off period. Thus, 
some rats appear to be inherently more or less sensitive to the reinforcing effects of 
MDMA. Following RU 24969 pretreatment, however, all of the rats met the criterion 
for acquisition of MDMA self-administration within the limits of the study (25 test 
sessions). We have suggested that the initial resistance to self-administration can be 
overcome by limiting the impact of 5-HT since a similar increase in the percentage of 
subjects that acquired MDMA self-administration was produced following neurotoxic 
5,7-DHT lesions in rats (Bradbury et al., 2014) and in 5-HT transporter knock-out rats 
(Oakly et al., 2014).  
In order to assess the impact of more specific 5-HT mechanisms on the 
acquisition of MDMA self-administration, the present study repeatedly administered 





regulate 5-HT1A and 5-HT1B receptors. We determined effects of the pretreatment by 
measuring behavioural responses that have been attributed to either 5-HT1B (RU 
24969-produced adipsia (Aronsen et al., 2014)) or 5-HT1A (8-OH-DPAT-produced 
hyperactivity (Hillegaart et al., 1996)) mechanisms.  
As previously reported (Aronsen et al., 2014), RU 24969 produced dose-
dependent adipsia. The dose-response curve for this response is relatively narrow; 
minimal effects were produced following administration of 0.3 mg/kg and maximal 
effects were produced following administration of  3.0 mg/kg (Aronsen et al., 2014). 
RU 24969 pretreatment decreased basal water consumption and when this was 
accounted for, RU 24969 pretreatment decreased the subsequent RU 24969-produced 
adipsic response. These findings are consistent with a rightward shift in the dose-
response curve and suggest a down-regulation of 5-HT1B receptors. 5-HT1B receptor 
down-regulation has previously been evidenced by decreased mRNA levels 
(Chennaoui et al., 2001; Hiroi & Neumaier, 2009) or decreased binding density 
(Kindlundh et al., 2003; Suzuki, Han, & Lucas, 2010), both of which could explain the 
present behavioural data.  
RU 24969 pretreatment also shifted the dose-response curve for 8-OH-DPAT-
produced hyperactivity to the right; the most pronounced effect of pretreatment was on 
hyperactivity produced by the lowest does of 8-OH-DPAT tested. This might explain 
why a similar pretreatment with RU 24969 failed to alter hyperactivity produced by a 
higher dose of 1.25 mg/kg 8-OH-DPAT (Oberlander et al., 1987).  
Although 8-OH-DPAT has appreciable affinity for the 5-HT7 receptor (Bard et 
al., 1993; Lovenberg et al., 1993), results from the previous chapter showed that 
hyperactivity produced by 8-OH-DPAT was attenuated by the selective receptor 
antagonist, WAY 100635, confirming a 5-HT1A receptor mechanism. Of interest, a 
similar RU 24969 pretreatment regimen also reduced the locomotor response to RU 
24969 (Callaway & Geyer, 1992), a behavioural response that we have attributed to 5-
HT1A receptor activation (Aronsen et al., 2014). Therefore, these findings are 
consistent with a down-regulation of 5-HT1A receptors following RU 24969 
pretreatment. 5-HT1A down-regulation has been shown via decreased agonist-
stimulated binding of [35S]GTPγS to G proteins (Fuss et al., 2013; Hensler, Vogt, & 
Gass, 2010), decreased receptor binding densities or immunoreactivity (Fuss et al., 





decreased protein levels (Iyo et al., 2009; S. Wang et al., 2009). It would be of great 
interest to determine which, if any, of these mechanisms can explain the present data.  
The available literature is consistent with the idea that MDMA self-
administration, like self-administration of other drugs of abuse, progresses as a result 
of sensitised dopamine and desensitised 5-HT responses. Thus, repeated exposure to 
MDMA increased dopamine (Colussi-Mas et al., 2010; Kalivas, Duffy, & White, 
1998) and decreased 5-HT (Baumann, Clark, Franken, et al., 2008; Reveron et al., 
2010; Shankaran & Gudelsky, 1999) synaptic output, as measured by in vivo 
microdialysis, dopamine antagonists reduced MDMA self-administration  (Brennan, 
Carati, Lea, Fitzmaurice, & Schenk, 2009; Daniela, Brennan, Gittings, Hely, & 
Schenk, 2004),  and dopamine, but not 5-HT,  agonists potentiated drug-seeking 
following extinction of MDMA self-administration (Schenk, Gittings, & Colussi-Mas, 
2011). 
MDMA preferentially releases 5-HT and the ensuing activation of post-
synaptic receptors impacts dopamine release, providing potential mechanisms for the 
enhanced dopamine response. In this study, both 5-HT1B and 5-HT1A receptor 
mechanisms were down regulated, as measured by behavioural assays. Given the 
selectivity of RU 24969 for 5-HT1A/1B receptors it is unlikely that alterations in a 
different receptor mechanism underlies the facilitated acquisition of self-administration 
found in the present study.  
Because activation of 5-HT1B receptors enhanced extracellular dopamine 
concentrations (Galloway et al., 1993; Hållbus et al., 1997; Iyer & Bradberry, 1996; 
O'Dell & Parsons, 2004; Yan & Yan, 2001a; Yan et al., 2004) it is possible that 
repeated administration of RU 24969 sensitised dopamine neurons independently of 
the effect on 5-HT1A and 5-HT1B receptors. A sensitised dopamine response to MDMA 
would be expected to facilitate the acquisition of MDMA self-administration. This 
seems unlikely, however, because RU 24969 pretreatment had no effect on 
amphetamine-produced hyperactivity. Although the amphetamine dose was chosen 
based on other sensitisation studies, it is possible that a sensitised dopamine response 
would have been observed if higher doses of amphetamine had been tested.  
Activation of 5-HT1B receptors enhanced basal dopamine neurotransmission 
(Alex & Pehek, 2007) and the dopaminergic response to drugs of abuse (O'Dell & 
Parsons, 2004; Parsons et al., 1999; Yan et al., 2005), so the down-regulation of these 





dopamine, cannot easily explain the facilitated self-administration. On the other hand, 
a wealth of data suggest that activation of 5-HT1A receptors is inhibitory to cocaine 
self-administration (Müller et al., 2007), possibly via inhibition of dopamine release 
(Ichikawa & Meltzer, 2000). Therefore, a down-regulation of this receptor subtype 
might be expected to disinhibit MDMA-produced dopamine, leading to more rapid 
acquisition of self-administration due to increased reinforcing effects. This might also 
explain the facilitated acquisition of MDMA self-administration in serotonin 
transporter knockout rats (Oakly et al., 2014), since this manipulation also desensitised 
5-HT1A receptor mechanisms (Homberg et al., 2008). 
5-HT1A receptors are widely localised in brain and are well-positioned to 
modulate activity in a large number of brain systems (Aznar, Qian, Shah, Rahbek, & 
Knudsen, 2003). Of importance, these receptors are localised on tyrosine hydroxylase 
immunoreactive cells in the VTA (Doherty & Pickel, 2001) and also in dopamine 
terminal regions in the NAc (Alex & Pehek, 2007). Systemic administration of 8-OH-
DPAT inhibited amphetamine-produced dopamine release in the NAc (Ichikawa et al., 
1995). The down-regulation produced by RU 24969 pretreatment would, therefore, be 
expected to disinhibit stimulated dopamine. Similar studies have not been conducted 
using MDMA, but this mechanism could explain the facilitated acquisition of self-
administration.   
The acquisition of self-administration is also influenced by factors in addition 
to the initial reinforcing effects of the drug and some of these factors are modified by 
5-HT1A receptor mechanisms. As explained in the General Introduction, increased 
impulsivity, anxiety, or learning, could be expected to facilitate the acquisition of 
MDMA self-administration.  
5-HT1A activation increased behavioural measures of impulsivity (Carli & 
Samanin, 2000). However, individual variability in impulsivity did not predict latency 
to acquisition of MDMA self-administration (Bird & Schenk, 2013). This might be 
because the impulsive response to 5-HT1A receptor agonists is due to autoreceptor 
activation (Carli et al., 2006; Lladó-­‐Pelfort et al., 2010; Winstanley et al., 2003). We 
have previously shown that repeated exposure to MDMA failed to alter 5-HT1A 
autoreceptor mechanisms (Schenk et al., 2013). Therefore, alterations in 5-HT1A-
mediated impulsivity are unlikely to have impacted the present results.  
A down-regulation of 5-HT1A receptors would be expected to reduce anxiety 





2000a, 2000b; File et al., 1996; File et al., 2000; Solati et al., 2011). However, higher 
levels of anxiety have been associated with self-administration (Dilleen et al., 2012; 
Homberg et al., 2002; Spanagel et al., 1995). Therefore an attenuation of 5-HT1A 
receptor-produced anxiety would not explain the facilitated acquisition of MDMA self-
administration. 
Reliable self-administration is often facilitated via Pavlovian conditioning 
processes by pairing delivery of the drug reinforcer with a discrete, discriminative 
stimulus, like a light, as was done in the present study (Di Ciano & Everitt, 2004). As 
explained in the General Introduction, strengthening of stimulus/reward associations is 
markedly inhibited by administration of 5-HT1A receptor agonists (Blair et al., 2004; 
Frick et al., 2015; Winsauer et al., 1999). These findings raise the possibility that 
activation of post synaptic 5-HT1A receptors pursuant to MDMA-stimulated 5-HT 
release limits the acquisition of MDMA self-administration, in some subjects, by 
interfering with associative learning. If so, our data suggest that this effect is mitigated 
by exposure to a regimen of RU 24969 pretreatment that down-regulated these 
receptor mechanisms, thereby facilitating MDMA self-administration as indicated by 
both a leftward and upward shift in the self-administration acquisition curves. This 
idea could be tested by administering the same RU 24969 pretreatment as was used in 
this study and assessing learning in a stimulus/reward association task.  If RU 24969 
pretreatment facilitated learning in such a task it would strengthen the claim that the 
facilitation of MDMA self-administration seen in the present study was associated 






Chapter 6: Predicting the acquisition of MDMA self-administration 
 
In the previous chapter, a manipulation that down-regulated 5-HT1A and 5-
HT1B receptors also greatly facilitated the acquisition of MDMA self-administration. 
As outlined in the discussion, it is possible that a down-regulation of these receptors 
could explain the facilitated acquisition. However, the correlational nature of that 
study makes it impossible to ascertain the role of alterations in 5-HT1A and/or 5-HT1B 
receptor mechanisms in the acquisition of MDMA self-administration. 
There is substantial evidence that the magnitude of MDMA-produced 5-HT 
release predicts the latency to acquire MDMA self-administration. A question remains 
as to what the mechanism underlying this effect might be. The results from the 
previous chapter raise the possibility that this mechanism involves individual 
variability in 5-HT1A and/or 5-HT1B receptor-mediated effects.  
Some evidence suggests that activation of these receptor subtypes modulates 
dopamine neurotransmission, providing a potential mechanism. For example, the 5-
HT1A receptor gonist, 8-OH-DPAT, inhibited amphetamine-produced increases in 
extracellular dopamine (Ichikawa et al., 1995; Kuroki et al., 1996). Thus, activation of 
5-HT1A receptors by MDMA-stimulated 5-HT would be expected to inhibit dopamine 
release. If so, this might explain why MDMA is, at least initially, not a very 
efficacious reinforcer. Activation of 5-HT1A receptors also impaired learning in a range 
of operant tasks (Blair et al., 2004; Frick et al., 2015; Meneses, 2007; Winsauer et al., 
1999). As a result, 5-HT1A activation during MDMA self-administration could inhibit 
learning processes associated with the acquisition of self-administration. Therefore, 
subjects with higher sensitivity to 5-HT1A receptor activation may be less likely to 
acquire MDMA self-administration, due to inhibition of dopamine release, and/or 
impaired ability to learn the operant task. The observation that RU 24969 pretreatment 
enhanced MDMA self-administration and down-regulated 5-HT1A receptors is 
consistent with this idea.  
5-HT1B receptor activation, on the other hand, augmented the increases in 
extracellular dopamine produced by cocaine (O'Dell & Parsons, 2004; Parsons et al., 
1999) or ethanol (Yan et al., 2005). Thus, the down-regulation of 5-HT1B receptors 
produced by RU 24969 pretreatment might be expected to reduce the reinforcing 
efficacy of MDMA.  Furthermore, intra-raphe injections of the neurotoxin, 5,7-DHT, 





Buhot, & Daszuta, 1998), and intraventricular infusion of 5,7-DHT produced an 
increase in 5-HT1B binding in the hypothalamus, entorhinal cortex, and substantia 
nigra (Manrique et al., 1998; Manrique et al., 1994; Manrique, Segu, Hery, Faudon, & 
François-Bellan, 1993; Weissmann, Mach, Oberlander, Demassey, & Pujol, 1986). 
This same lesion facilitated MDMA self-administration (Bradbury et al., 2014). In 
contrast, intraventricular infusion of 5,7-DHT had no impact on 5-HT1A binding in 
substantia nigra, PFC, hippocampus, hypothalamus, or amygdala (Hensler, Kovachich, 
& Frazer, 1991; Lawrence, Olverman, Shirakawa, Kelly, & Butcher, 1993; Weissmann 
et al., 1986). Thus, the role of 5-HT1B receptor populations in MDMA self-
administration is not clear. Acquisition was facilitated by separate manipulations that 
produced both an up- and down-regulation of 5-HT1B receptors, respectively. It is 
therefore possible that the acquisition of MDMA self-administration is not related to 5-
HT1B receptor populations.  
The purpose of the following studies was to determine whether individual 
variability in 5-HT1A and/or 5-HT1B receptors predicted the latency to acquisition of 
MDMA self-administration. To this end, the behavioural responses to the 5-HT1A 
receptor agonist, 8-OH-DPAT, or the 5-HT1B/1A receptor agonist, RU 24969, were 
assessed before MDMA self-administration commenced. Furthermore, to test the idea 
that RU 24969 pretreatment facilitated acquisition of MDMA self-administration via a 
down-regulation of 5-HT1A receptors, separate groups of rats were administered the 5-
HT1A receptor antagonist, WAY 100635, or vehicle, before each self-administration 
session. If 5-HT1A receptor activation does inhibit MDMA self-administration, 
pretreatment with WAY 100635 would be expected to facilitate acquisition. 
Method 
Subjects and procedures 
 Male Sprague-Dawley rats underwent catheter surgery for self-administration, 
as outlined in the General Methods section. Testing began after recovery to pre-
surgery weight. 
The hyperlocomotor response to 8-OH-DPAT was assessed using the standard 
locomotor activity methods outlined in the General Methods section. Rats were placed 
in the activity chambers for 30 minutes, followed by 8-OH-DPAT (0.1, 0.3 mg/kg, s.c., 
n=24 and 30 respectively) administration, and locomotor activity was measured for 





showed both doses produced hyperactivity with considerable between-subject 
variability. 
 Adipsia produced by RU 24969 was assessed using the standard water 
consumption methods outlined in the General Methods section. RU 24969 (1.0 mg/kg, 
s.c., n=13) was administered 15 minutes before water bottles were reintroduced. This 
dose was chosen because in previous studies it produced an adipsic response with 
considerable between-subject variability (Aronsen et al., 2014).  
MDMA self-administration, as outlined in the General Methods, began the day 
after the behavioural response to 8-OH-DPAT or RU 24969 was measured. Self-
administration was conducted during 2 hour daily sessions, 6 days per week. Each self-
administration session began with an experimenter-delivered infusion of drug. 
Thereafter, depression of the active lever produced an infusion of MDMA according to 
an FR1 schedule. Responses on the active and inactive levers were recorded. Every 
seventh day catheters were infused with sodium pentobarbital (20.0 mg/kg, i.v.). 
Failure to demonstrate an immediate loss of the righting reflex suggested a loss of 
catheter patency and the rat was excluded from the study. Catheter patency was lost in 
5 rats (4 after 8-OH-DPAT-produced hyperactivity (3 in the 0.1 mg/kg group, 1 in the 
0.3 mg/kg group), 1 after RU 24969-produced adipsia), and one rat self-administered a 
lethal dose of MDMA on the first day (0.3 mg/kg 8-OH-DPAT group). The same 
acquisition criterion was used as in the last chapter – a total of 90 infusions (90 mg/kg) 
self-administered. In order to minimise the number of subjects required, testing 
continued for 35 sessions in the groups assigned to 0.3 mg/kg 8-OH-DPAT and 1.0 
mg/kg RU 24969. Testing in the 0.1 mg/kg 8-OH-DPAT group continued for 25 
sessions, whereupon subjects were used for a different study. 
Using the same self-administration procedure, separate groups of rats were 
pretreated with either saline vehicle, or the 5-HT1A receptor antagonist, WAY 100635 
(1.0 mg/kg, s.c., n=7 per group) 15 minutes before each daily self-administration 
session. Of the 14 rats that started self-administration, 4 were removed from the 
experiment due to loss of catheter patency (3 in the vehicle group, 1 in the WAY 
100635 group).  
Statistical analyses 
Behavioural responses to either 8-OH-DPAT or RU 24969 were correlated 
with latency to acquisition of MDMA self-administration using a Pearson's product-





were not included in these analyses. Analysis of the effect of WAY 100635 
pretreatment on self-administration was not possible due to a high attrition rate, but 
raw data are presented.  
Results 
 Out of a total of 67 rats that started the locomotor and adipsia studies, 39 met 
the acquisition criterion within 25 sessions, and a further 9 met the criterion between 
26 and 35 sessions.  
 Figure 6.1 shows the distribution of days to meet the acquisition criterion and 
locomotor response to 0.1 mg/kg 8-OH-DPAT. There was no significant correlation 
between these two variables (r(16)=-0.21, p=0.40). 
 
 
Fig 6.1 Scatterplot	  of	  days	  to	  acquire	  MDMA	  self-­‐administration	  (y-­‐axis)	  and	  
locomotor	  response	  to	  0.1	  mg/kg	  8-­‐OH-­‐DPAT	  (x-­‐axis).	  	  
 
Similarly, there was no correlation between days to acquisition and locomotor 
response to 0.3 mg/kg 8-OH-DPAT (r(18)=0.004, p=0.99) (see figure 6.2). 














































Fig 6.2 Scatterplot	  of	  days	  to	  acquire	  MDMA	  self-­‐administration	  (y-­‐axis)	  and	  
locomotor	  response	  to	  0.3	  mg/kg	  8-­‐OH-­‐DPAT	  (x-­‐axis).	  	  
 
 The distribution of days to acquire MDMA self-administration and the adipsic 
response to RU 24969 is shown in figure 6.3. Analysis showed no significant 
correlation between the two variables (r(7)=0.26, p=0.49). 






















Fig 6.3 Scatterplot	  of	  days	  to	  acquire	  MDMA	  self-­‐administration	  (y-­‐axis)	  and	  adipsic	  
response	  to	  1.0	  mg/kg	  RU	  24969	  (x-­‐axis).	  	  
 
 Data from the WAY 100635 pretreatment groups would have been analysed 
using a log-rank test to compare Kaplan-Meier survival estimates (Kaplan & Meier, 
1958), but given the high attrition rate in the control group this analysis would not be 





administration data over sessions are presented in figure 6.4. It is interesting to point 
out that, while escalation of intake is evident from around day 6 in the control group, 
there is no escalation in the WAY 100635 group. This pattern continued beyond day 
15, in fact by day 25 the highest total intake in the WAY 100635 pretreatment group 
was 41 mg/kg. The high variability in the vehicle control group from day 10 is to be 
expected, because as we have previously shown, intake in some rats increases around 
this time point (Schenk et al., 2012). Data after day 15 are not presented because, by 
that stage, only 3 rats remained in the control group (1 reached acquisition criteria, 3 
lost catheter patency). Table 6.1 shows the raw data for the number of infusions over 
different self-administration sessions. These data further illustrate the variability in the 
vehicle group, due to increased self-administration in some subjects, and is roughly in 
line with the expectation that approximately 50% of control subjects would acquire 
MDMA self-administration.  
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Fig 6.4 Number	  of	  MDMA	  infusions	  self-­‐administered	  across	  sessions	  in	  rats	  treated	  
with	  either	  WAY	  100635	  (1.0	  mg/kg)	  or	  vehicle,	  15	  minutes	  before	  self-­‐administration	  















Session 1 Session 5 Session 10 Session 15 
       
WAY 100635 




1 0 removed removed 
 
Rock Wren 4 0 3 1 
 




12 0 0 1 
 
Spotless Crake 0 1 0 0 
 




1 1 2 1 
       Vehicle 
      
 
















1 0 0 0 
 
White Heron 2 3 removed removed 
 
Yellowhead 2 0 1 0 
     
Table 6.1	  The	  number	  of	  MDMA	  infusions	  (1.0	  mg/kg/infusion)	  self-­‐administered	  by	  
subjects	  treated	  with	  either	  the	  5-­‐HT1A	  	  receptor	  antagonist,	  WAY	  100635,	  or	  saline	  
vehicle,	  15	  minutes	  before	  each	  self-­‐administration	  session.	  
 
Discussion 
 These studies failed to show an association between behavioural response to 5-
HT1A or 5-HT1B activation, and latency to acquire MDMA self-administration. These 
results were surprising given that, in the previous chapter, a treatment that down-
regulated both receptor subtypes also facilitated acquisition of MDMA self-
administration. Furthermore, lower sensitivity of 5-HT1A, or greater sensitivity of 5-
HT1B, receptors would be expected to enhance the dopaminergic response to MDMA, 
which would be expected to enhance self-administration. Thus, it appears that basal 
variability in 5-HT1A and 5-HT1B receptors is not associated with the variability in 
acquisition of MDMA self-administration.  
 These results might suggest that facilitated self-administration after RU 24969 
pretreatment reported in the previous chapter was not due to the effects of the 
pretreatment on 5-HT1A or 5-HT1B receptors. Indeed, a significant correlation between 
behavioural response and latency to acquisition in the present studies would have been 
evidence for a role of 5-HT1A and/or 5-HT1B receptors in the initial reinforcing effects 





of RU 24969 pretreatment on MDMA self-administration was independent of the 
effects on 5-HT1A or 5-HT1B receptors. Firstly, RU 24969 is reasonably selective for 
these two receptor subtypes, making a non-selective effect less likely. Furthermore, it 
is possible that the natural variability in the behaviours measured in this study was not 
substantial enough to show an effect. For example, the mean activity count after 0.1 
mg/kg 8-OH-DPAT in the present study was 1003 (SD=348), but after RU 24969 
pretreatment this mean was 378 (SD=164). Thus, it is possible that lower sensitivity to 
8-OH-DPAT is indeed predictive of latency to acquire MDMA self-administration, but 
that significantly lower levels of sensitivity are required.  
 Further study is required to determine the relative roles of 5-HT1A and 5-HT1B 
receptors in the facilitation of MDMA self-administration after RU 24969 
pretreatment. Pretreatment with RU 24969 and either the 5-HT1A receptor antagonist, 
WAY 100635, or the 5-HT1B receptor antagonist, GR 127935, would help to clarify 
the roles of each receptor. 
 There was an unfortunately high attrition rate in the WAY 100635 pretreatment 
study. This attrition rate likely reflects a procedural problem during catheter surgery 
that has since been identified. Measures have now been put in place to avoid such 
levels of attrition in future. The subsequently small size of the saline pretreatment 
group precludes meaningful comparisons between the WAY 100635 pretreatment 
group and its appropriate control. However, our laboratory, and this thesis, have shown 
that approximately 50% of rats acquire MDMA self-administration (Bradbury et al., 
2014; Schenk et al., 2012), and it seems unlikely that saline administration would alter 
this acquisition rate. Therefore, it becomes interesting that responding for MDMA was 
so low in the WAY 100635 group. If these findings were replicated in a larger sample, 
and with an appropriate control, the data would provide evidence for the suggestion 
that 5-HT1A receptor activation is required for the development of MDMA self-
administration.  
If so, it would be difficult to reconcile these data with the RU 24969 
pretreatment data that showed a down-regulation of 5-HT1A receptors was associated 
with enhanced MDMA self-administration. Given the limited scope of the present 
study, it is not possible to rule out a non-specific effect of WAY 100635. Data from 
chapter 4 suggest that this dose of WAY 100635 does not supress locomotor 
responding. Furthermore, data from the first self-administration session, and other 





an operant response after acute WAY 100635 administration. Thus it seems unlikely 
that the low levels of responding after WAY 100635 administration were due to motor 
effects. There were no differences between the weights of subjects in the two groups 
throughout the experiment (data not shown), suggesting there was no effect of WAY 
100635 on eating or drinking. 
It might be expected that repeated administration of an antagonist would 
upregulate receptor populations. Indeed, administration of a high dose (3 mg/kg) of 
WAY 100635 twice per day for 3 days increased 5-HT1A immunoreactivity in the 
hippocampus and cortex (Abbas, Nogueira, & Azmitia, 2007). An up-regulation of 5-
HT1A receptors might inhibit self-administration via enhanced inhibition of dopamine. 
Alternatively, WAY 100635 may have protected 5-HT1A receptors from important 
neuroadaptations in response to high levels of 5-HT. During self-administration 
session 1 I noticed that the rats in the WAY 100635 group that self-administered a 
large dose of MDMA did not show the characteristic set of symptoms (hyperthermia, 
wetness, ‘eagle-fear’, bleeding nose) typically associated with initial self-
administration of high doses. Anecdotally, repeated self-administration of high doses 
of MDMA produces tolerance to these effects. Thus, WAY 100635 may have been 
preventing neuroadaptations that produce tolerance to some of the aversive effects of 
MDMA. Clearly, more research would be required to determine if this is the case. 
 The results of the present study failed to show an association between basal 
responses to 5-HT1A or 5-HT1B receptor activation and latency to acquire MDMA self-
administration. However, the results of the previous chapter, and inferences drawn 
from the WAY 100635 study in this chapter, raise the possibility that neuroadaptations 
in 5-HT1A and/or 5-HT1B receptors are important for the progression of MDMA self-
administration. As outlined above, basal variability in these receptor subtypes may not 
be substantial enough to allow for meaningful analysis. On the other hand, if changes 
in these receptor subtypes underlie the development of MDMA as an efficacious 
reinforcer, it might be possible to detect differences in these receptor populations after 







Chapter 7: Response to 5-HT1A and 5-HT1B receptor agonists after self-
administration 
 
Parts of this chapter have been adapted from: 
Aronsen & Schenk (2016). MDMA self-administration fails to alter the response to 5-
HT1A and 5-HT1B agonists. Psychopharmacology, 233 (7), 1323-1330. DOI 
10.1007/s00213-016-4226-9 
with permission from the publisher (Appendix A). 
Some users regularly consume large quantities of ecstasy (Cottler et al., 2001; 
Degenhardt, Barker, & Topp, 2004; Topp, Hall, & Hando, 1997), and repeated ecstasy 
use produces a range of negative consequences, including cognitive and emotional 
deficits. While these deficits are worrisome in and of themselves, it has been suggested 
that they could also facilitate further ecstasy taking, and thus contribute to the 
development of an SUD (Schenk, 2009; Schenk & Aronsen, 2015). The mechanisms 
underlying these deficits are not, however, well understood. 
Ecstasy users showed deficits in learning (Wagner et al., 2013), and in attention 
and memory (McCann, Mertl, et al., 1999) compared to ecstasy-naïve controls or those 
with limited ecstasy use. Ecstasy users reported higher levels of depression, 
impulsiveness, and sleep disturbances than poly-drug users who did not use ecstasy 
(Taurah et al., 2014). These cognitive and behavioural deficits were persistent, 
suggesting that regular ecstasy use may cause long-lasting neuroadaptations (Parrott, 
2013b). 
Animal studies have shown that a number of these adverse effects associated 
with ecstasy use are modulated by pharmacological manipulation of 5-HT receptors. 
For example, the 5-HT1A receptor agonist, 8-OH-DPAT, impaired learning and 
memory in water maze (Carli & Samanin, 1992),  passive avoidance (Carli, Tranchina, 
& Samanin, 1992), and conditioned reinforcement (Meneses, 2007) tasks, while the 5-
HT1A receptor antagonist, WAY 101405, improved learning in the Morris water maze 
(Hirst et al., 2008). 5-HT1A receptor agonists and antagonists also altered performance 
in the forced swim test and conditioned stress-induced ultrasonic vocalisations (Assié 
et al., 2010; Lucki, Singh, & Kreiss, 1994) and altered sleep and wakefulness, as 
measured by EEG and EMG (Monti & Jantos, 1992; Monti et al., 1990). Activation of 





time task (Carli & Samanin, 2000), while the 5-HT1A receptor antagonist, WAY 
100635, supressed impulsive action (Ohmura et al., 2013). 
Pharmacological manipulation of  the 5-HT1B receptor subtype also affected 
learning and memory as measured by a conditioned reinforcement task (Meneses, 
2001, 2007), altered EEG and EMG recordings of sleep and wakefulness (Bjorvatn & 
Ursin, 1994; Monti, Monti, Jantos, & Ponzoni, 1995), and  affected immobility time in 
the forced swim test (Dawson et al., 2006; Tatarczynska, Klodzinska, Stachowicz, & 
Chojnacka-Wojcik, 2004). Therefore, it is possible that some of the cognitive and 
behavioural deficits that accompany ecstasy use might be due to MDMA-produced 
neuroadaptations in these receptor mechanisms.  
A small number of studies have assessed the effects of repeated exposure to 
MDMA on 5-HT1A and 5-HT1B receptor mechanisms.  Repeated experimenter-
administered MDMA reduced 5-HT1A binding in the dorsal raphe, suggesting a down-
regulation of 5-HT1A autoreceptors, and increased 5-HT1A binding in the frontal cortex, 
suggesting an up-regulation of 5-HT1A heteroreceptors (Aguirre, Ballaz, Lasheras, & 
Del Rio, 1998; Aguirre, Frechilla, García-­‐Osta, Lasheras, & Del RIo, 1997; Aguirre, 
Galbete, Lasheras, & Del Río, 1995). These effects were only produced following 
exposure to high doses (2x20-30 mg/kg/day, 4 consecutive days); exposure to lower 
doses (4x5 mg/kg/day, 2 consecutive days (McGregor et al., 2003)), or intermittent 
doses (2x10mg/kg/day, every 5th day (Piper, Vu, Safain, Oliver, & Meyer, 2006)) of 
MDMA failed to alter cortical or subcortical 5-HT1A densities. Repeated 
administration of  racemic MDMA increased 5-HT1B receptor mRNA (Kindlundh-
Högberg, Svenningsson, & Schiöth, 2006), and receptor binding densities were 
increased in some brain regions, but decreased in others, after repeated MDMA 
administration (McGregor et al., 2003). Repeated administration of (+) MDMA, 
however, failed to produce persistent changes in 5-HT1B mRNA or 5-HT1B receptor 
binding (Sexton, McEvoy, & Neumaier, 1999). 
Functional evidence for these receptor changes is equivocal. Repeated 
administration of MDMA attenuated the autoreceptor-mediated decrease in 5-HT 
release produced by the 5-HT1A receptor agonist, F13640, in mice (Lanteri et al., 
2014). Repeated administration of MDMA did not, however, alter 8-OH-DPAT-
produced lower lip retraction or hypolocomotion, behaviours associated with 5-HT1A 
autoreceptor activation (Schenk et al., 2013). On the other hand, 8-OH-DPAT-





study (Aguirre et al., 1998) but unchanged in others (McNamara, Kelly, & Leonard, 
1995; Mechan, O'Shea, Elliott, Colado, & Green, 2001; Piper et al., 2006). MDMA 
pretreatment also attenuated the 8-OH-DPAT-produced 5-HT syndrome (Piper et al., 
2006) and forepaw treading (Granoff & Ashby, 2001), but had no effect on the 
prosocial response (Thompson, Callaghan, Hunt, & McGregor, 2008), or the 
hyperactive response (Granoff & Ashby, 2001) to 8-OH-DPAT. Differences might be 
due to a number of paradigmatic variables including dosing regimen and subject 
sample. 
The hyperactive response to the 5-HT1B/1A receptor agonist, RU 24969, was 
decreased after repeated administration of racemic MDMA (Callaway & Geyer, 1992), 
but enhanced after repeated administration of the (+) MDMA isomer (McCreary, 
Bankson, & Cunningham, 1999). It was suggested that this behavioural response to 
RU 24969 reflected 5-HT1B receptor activation (Callaway & Geyer, 1992), but some 
studies have suggested that RU 24969-produced hyperactivity is due to 5-HT1A 
receptor activation (Aronsen et al., 2014; Kalkman, 1995). Repeated MDMA 
administration (2x20 mg/kg/day, 4 consecutive days) failed, however, to alter 
hyperactivity produced by the 5-HT1A receptor agonist, 8-OH-DPAT (Granoff & 
Ashby, 2001). Therefore, the effect of MDMA exposure on the function of 5-HT1B 
receptors is equivocal.  
Studies on the effects of repeated exposure to MDMA have generally 
administered a regimen that produces extensive, and persistent, neurotoxic effects. For 
example, alterations in 5-HT1A binding, decreased tissue levels of 5-HT (Aguirre et al., 
1998) and decreased 5-HT transporter binding (Aguirre et al., 1995) were produced by 
exposure to high doses (2x30mg/kg/day, 4 consecutive days) of MDMA. This high 
level of exposure is rarely, if ever, experienced by ecstasy users (D. Hansen et al., 
2001; Parrott, 2005; Verheyden et al., 2003), which questions the external validity of 
findings derived from these experiments (Baumann & Rothman, 2009; Cole & 
Sumnall, 2003; De La Garza et al., 2007; Meyer et al., 2008). 
 MDMA exposure during self-administration is quite different from most 
studies that employ experimenter-administered MDMA. In rats, MDMA self-
administration is initially limited, but with repeated testing intake gradually increases 
for some subjects (Schenk et al., 2012). Given the differences in exposure as well as 
the well documented differences between effects of contingent and non-contingent 





administered MDMA might be expected to produce different effects than those seen 
after experimenter-administration. Indeed, self-administered MDMA produced smaller 
deficits in tissue levels of 5-HT compared to high dose experimenter-administered 
MDMA (Do & Schenk, 2011; Scanzello et al., 1993; Schenk et al., 2007) even though 
the total amount self-administered (165-350 mg/kg over 20-30 days of testing) was 
greater than is generally administered to produce extensive neurotoxicity (20-80 mg/kg 
in a single day). Additionally, intermittent or low dose exposure to MDMA was 
neuroprotective against the toxic effects of subsequent high dose administrations 
(Bhide et al., 2009; Piper et al., 2010). 
Because of the limited amount of information concerning effects of self-
administered MDMA on brain and/or behaviour and the potential role of specific 
neuroadaptations in some of the adverse effects of MDMA, this study determined the 
effect of extensive MDMA self-administration on behavioural responses to 5-HT1A 
and 5-HT1B receptor agonists.  
 
Method 
Subjects and procedures 
Male Sprague-Dawley rats underwent catheter surgery as outlined in the 
General Methods section.   
MDMA self-administration 
Rats were randomly assigned to self-administer either MDMA, or vehicle, 
using the standard self-administration equipment outlined in the General Methods 
section. Self-administration was conducted during 2 hour daily sessions, 6 days per 
week. Initially, active lever responses were reinforced with MDMA (1.0 mg/kg), or 
vehicle (0.1 ml) infusions according to an FR1 schedule. The vehicle control group 
continued on this contingency for the remainder of the experiment. The MDMA self-
administration group continued with this contingency until a total of 90 infusions had 
been self-administered, or 25 test sessions had been completed, whichever came first. 
Rats that failed to self-administer 90 infusions within this 25 day cut-off period 
(approximately 50%, as we have previously reported (Schenk et al., 2012)) were not 
tested further. For those that met this criterion, the dose of MDMA was decreased to 
0.5 mg/kg. The reinforcement schedule was then increased to FR2 for a minimum of 5 
days and then FR5. Testing continued until a total intake of 350 mg/kg MDMA was 





reach a total intake of 350 mg/kg. Where possible, each rat in the vehicle self-
administration group was matched to a rat in the MDMA self-administration group to 
ensure a comparable number of test sessions. A total of 73 rats met the initial criterion 
of 90 infusions of MDMA (1.0 mg/kg/infusion) within the 25 day cut-off period. Of 
these, some did not progress further due to loss of catheter patency (n=1), failure to 
increase responding when the FR schedule was increased (n=12), or MDMA toxicity 
(n=3). The remaining rats (n=57) completed testing and self-administered 350 mg/kg 
MDMA. A total of 62 rats initiated vehicle self-administration, but 1 was removed 
from the study due to an inner ear infection, leaving a total of 61 that self-administered 
vehicle. Separate groups of rats that completed self-administration testing were then 
randomly assigned to groups to measure the effects of either 8-OH-DPAT-produced 
hyperactivity or RU 24969-produced adipsia. 
Locomotor activity 
Locomotor activity was assessed 2 days after the last self-administration 
session. Rats were placed in the testing chamber for 30 minutes, followed by an 
injection of 8-OH-DPAT (0.0, 0.03, 0.1, 0.3, 1.0 mg/kg, s.c., n=5-7 per group). 
Horizontal activity counts were recorded in 5 minute intervals during the 30 minutes 
prior to, and 60 minutes following, the 8-OH-DPAT injection.  
Water consumption 
The day following the last self-administration session, water bottles were 
removed from the home cages for 24 hours. Fifteen minutes before water bottles were 
reintroduced, RU 24969 (0, 0.3, 1.0, 3.0 mg/kg, s.c., n= 6-9 per group) was 
administered, as previously reported (Aronsen et al., 2014). Water bottles were 
weighed before, and after 30 minutes of access, to measure water consumption.  
Data analysis 
Effects of 8-OH-DPAT on locomotor activity were analysed by a 2 (self-
administration group) × 5 (Dose of 8-OH-DPAT) ANOVA. RU 24969-produced 




The average amount of MDMA that was self-administered during the last 5 





the number of rats that self-administered 350 mg/kg of MDMA as a function of test 
session. Most of the rats met the criterion within 25-44 test sessions. The mean number 
of test sessions required to complete testing was 35.7 (SEM=1.3). The average number 
of days to complete testing reported in this study is similar to data that we have 
previously reported. For example, an average of 37 +/- 2.3 days was required to self-
administer a slightly lesser total of 315 mg/kg that resulted in decreased tissue levels of 
5-HT (Do & Schenk, 2011). The vehicle self-administration group was tested for an 
average of 36 sessions (SEM= 1.4). These rats were matched to the MDMA self-
administration rats to minimise any confounds associated with the self-administration 
procedure. 
 














































Fig. 7.1 Frequency	  distribution	  of	  the	  number	  of	  rats	  that	  self-­‐administered	  350	  
mg/kg	  MDMA	  as	  a	  function	  of	  test	  session. 
 
8-OH-DPAT-produced hyperactivity  
 Figure 7.2 shows the hyperactive response to 8-OH-DPAT after self-
administration of MDMA or vehicle. ANOVA showed an effect of 8-OH-DPAT dose 
(F(4,47) = 27.27, p<0.01, ɳp2= 0.70), but no effect of self-administration (F(1,47) = 
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Fig. 7.2 Effect	  of	  MDMA	  self-­‐administration	  (350	  mg/kg	  total)	  on	  8-­‐OH-­‐DPAT-­‐
produced	  hyperactivity.	  Rats	  in	  these	  groups	  met	  the	  criterion	  of	  350	  mg/kg	  MDMA	  
after	  25-­‐58	  test	  sessions.	  Symbols	  represent	  mean	  ±	  SEM.	  n	  =	  5-­‐7	  per	  group.	  
 
RU 24969-produced adipsia 
 As we have previously shown (Aronsen et al., 2014), RU 24969 produced a 
dose-dependent adipsic response (F(3,51) = 65.68, p<0.01, ɳp2= 0.79; Fig 7.3). There 
was no statistically significant effect of self-administration (F(1,51) = 2.86, p=0.10) 





















Fig. 7.3 Effect	  of	  MDMA	  self-­‐administration	  (350	  mg/kg	  total)	  on	  RU	  24969-­‐produced	  
adipsia.	  Rats	  in	  these	  groups	  met	  the	  criterion	  of	  350	  mg/kg	  MDMA	  after	  20-­‐58	  test	  






MDMA self-administration failed to alter 8-OH-DPAT-produced hyperactivity, 
or RU 24969-produced adipsia. It is unlikely that the MDMA exposure was 
insufficient because similar or lower doses of self-administered MDMA produced 
decreases in 5-HT transporter binding (Schenk et al., 2007), decreases in tissue levels 
of 5-HT (Do & Schenk, 2011; Schenk et al., 2011), and behavioural deficits (Do & 
Schenk, 2011). Instead, the present data suggest that 5-HT1A and 5-HT1B receptor 
mechanisms are not altered by MDMA self-administration. 
These findings were surprising because prolonged activation by MDMA-
produced 5-HT release might have been expected to down-regulate these receptor 
subtypes. Alternatively, the decrease in MDMA-produced 5-HT release that has been 
reported following MDMA self-administration (Reveron et al., 2010) might have been 
expected to result in a compensatory up-regulation of these receptors. A neurotoxic 
5,7-DHT lesion increased 5-HT1B receptor binding (Compan et al., 1998; Crino, Vogt, 
Volicer, & Wiley, 1990; Frankfurt, Mendelson, McKittrick, & McEwen, 1993; 
Manrique et al., 1998; Manrique et al., 1994; Manrique et al., 1993; Offord et al., 
1988; Weissmann et al., 1986). Furthermore, repeated agonist treatment decreased 5-
HT1B receptor binding (Pranzatelli & Razi, 1994), and behavioural responses to 5-
HT1A (De Souza, Goodwin, Green, & Heal, 1986; Hensler, 2003) and 5-HT1B (Frances 
& Monier, 1991) receptor agonists.  
Repeated exposure to other drugs that increase synaptic 5-HT levels altered 5-
HT1A and 5-HT1B receptors. For example, chronic treatment with the selective 5-HT 
reuptake inhibitor (SSRI), fluoxetine, decreased 5-HT1B receptor binding (Duncan, 
Hester, Hopper, & Franklin, 2010). It is important to note, however, that many of the 
effects of SSRI treatment reflect alterations that are most likely attributed to 
autoreceptor, rather than post-synaptic receptor, desensitisation. For example, repeated 
treatment with fluoxetine (8 mg/kg/day, 2-3 weeks) reduced 5-HT1A mRNA in the 
raphe nuclei (Le Poul et al., 2000). Higher doses also produced a decrease in 5-HT1A 
receptor binding (Welner, De Montigny, Desroches, Desjardins, & Suranyi-­‐Cadotte, 
1989) and 8-OH-DPAT stimulated [35S]GTPγS binding (Castro et al., 2003) in the 
dorsal raphe. Repeated exposure to MDMA failed to alter a number of 5-HT1A 
autoreceptor mediated behavioural or neurochemical responses (Schenk et al., 2013), 
suggesting differences between effects of these two classes of drugs.  Repeated 





Nowak, Dlaboga, & Filip, 2003) and 5-HT1B mRNA (Hoplight, Vincow, & Neumaier, 
2007). Cocaine self-administration also increased the behavioural and physiological 
responses to 5-HT1A and 5-HT1B receptor agonists (O'Dell, Manzardo, Polis, Stouffer, 
& Parsons, 2006).  
The present data do not rule out the possibility that repeated ecstasy use leads 
to cognitive and behavioural deficits via dysregulation of these receptor subtypes, but 
our results suggest that other 5-HT receptors are more likely to make important 
contributions. One potential candidate is the 5-HT2A receptor, because it has also been 
implicated in impulsivity (Cunningham & Anastasio, 2014) , sleep (Sharpley, Elliott, 
Attenburrow, & Cowen, 1994) and memory (Dhonnchadha & Cunningham, 2008; 
Howell & Cunningham, 2015), behaviours that are impacted by regular ecstasy use. 
MDMA exposure increased 5-HT2A receptor binding (Benningfield & Cowan, 2013; 
Urban et al., 2012) and behavioural responses to the 5-HT2A/2C receptor agonist, DOI 
(Biezonski, Courtemanche, Hong, Piper, & Meyer, 2009). Additional studies assessing 









MDMA is widely used in the form of the street drug, ecstasy. Regular use of 
ecstasy has been associated with a number of behavioural and neurochemical deficits, 
and some of these deficits likely contribute to further, problematic drug taking. While 
most drugs of abuse primarily enhance dopamine neurotransmission, MDMA 
preferentially releases 5-HT. This 5-HT release has been hypothesised to inhibit the 
dopaminergic response to MDMA, thus inhibiting the reinforcing efficacy of MDMA. 
However, with repeated exposure to MDMA, the 5-HTergic response is attenuated, 
disinhibiting the dopaminergic response and making MDMA similar to other drugs of 
abuse. The mechanism for this 5-HTergic inhibition of dopamine is not known, but 
one possibility is that activation of specific 5-HTergic receptors, via MDMA-produced 
5-HT release, alters the dopaminergic response to MDMA. Of the 14 different 5-HT 
receptors, the 5-HT1A and 5-HT1B receptors were investigated because of a 
documented role in regulating basal and drug-produced dopamine release, as well as 
behaviours associated with ecstasy use. The purpose of this thesis was to test the role 
of these receptors in the self-administration of MDMA in rats, and to document any 
changes in these receptor populations produced by MDMA.  
Firstly, appropriate behavioural assays for 5-HT1A and 5-HT1B receptor 
activation needed to be identified. Latent inhibition, measured using the conditioned 
taste aversion paradigm, was chosen as a behavioural response to 5-HT1B receptor 
activation, but this response was confounded by the adipsic response to the 5-HT1B/1A 
receptor agonist, RU 24969. After further testing, I found that this adipsic response to 
RU 24969 was dose-dependent, and blocked by a 5-HT1B, but not a 5-HT1A, receptor 
antagonist. Thus, the adipsic response to RU 24969 was chosen as a behavioural 
measure of 5-HT1B receptor activation. In contrast, the hyperactive response to RU 
24969 was blocked by a 5-HT1A, but not a 5-HT1B, receptor antagonist. A similar result 
was obtained with the more selective and well characterised 5-HT1A receptor agonist, 
8-OH-DPAT, thus the locomotor response to 8-OH-DPAT was chosen as a 
behavioural response to 5-HT1A receptor activation.  
To test whether 5-HT1A and/or 5-HT1B receptors regulated MDMA self-





impact on the acquisition of MDMA self-administration. To this end, rats were 
repeatedly administered a high dose of the 5-HT1B/1A receptor agonist, RU 24969, 
before commencing MDMA self-administration. The pretreatment down-regulated 5-
HT1A and 5-HT1B receptors, and greatly facilitated the acquisition of MDMA self-
administration. Because drug produced dopamine release is inhibited by activation of 
5-HT1A receptors, but enhanced by 5-HT1B receptors, the impact of RU 24969 
pretreatment on acquisition of MDMA self-administration was hypothesised to be 
associated with the down-regulation of 5-HT1A receptors. 
The role of 5-HT1A and 5-HT1B receptors in the acquisition of MDMA self-
administration was further tested by investigating the relationship between basal 
responses to receptor activation and latency to acquire MDMA self-administration. 
Based on the role of these receptors in regulating the dopaminergic response to other 
drugs of abuse, and the facilitated acquisition of MDMA self-administration after 
repeated exposure to RU 24969, it was expected that behavioural responses to 
activation of these receptors would predict the latency to acquire MDMA self-
administration. This hypothesis was not supported in any of the studies. Furthermore, 
because an inhibitory role of 5-HT1A receptor activation in the acquisition of MDMA 
self-administration was hypothesised, I investigated the effect of 5-HT1A receptor 
antagonist treatment during the acquisition phase. Again, results did not support the 
hypothesis, in fact, the results suggested that 5-HT1A receptor blockade inhibited 
MDMA self-administration.  
Acquisition studies had returned mainly negative results, but there was still 
reason to believe that 5-HT1A and/or 5-HT1B receptors regulated the self-administration 
of MDMA. Therefore, behavioural responses to 5-HT1A or 5-HT1B receptor activation 
were measured after the self-administration of a high dose of MDMA. It was expected 
that prolonged exposure to MDMA would alter behavioural responses to agonist 
administration, but again this hypothesis was not supported. Although these studies do 
not rule out the possibility of 5-HT1A or 5-HT1B receptor neuroadaptations in response 
to MDMA self-administration, they do suggest that other 5-HT receptors are more 
likely to make important contributions. 
Synthesis of results 
Overall, the data presented in this thesis are difficult to reconcile. On the one 





would modulate the reinforcing efficacy of MDMA, and that these receptor 
mechanisms would be altered by prolonged exposure to MDMA. Furthermore, the RU 
24969 pretreatment, that down-regulated 5-HT1A and 5-HT1B receptors, also facilitated 
the acquisition of MDMA self-administration. On the other hand, behavioural 
responses to 5-HT1A and 5-HT1B receptor activation did not predict the acquisition of 
MDMA self-administration, acquisition was blocked by the 5-HT1A receptor 
antagonist, WAY 100635, and there were no changes in dose response curves for 5-
HT1A or 5-HT1B mediated responses after the self-administration of a high dose of 
MDMA.  
Together, the most likely explanation for the results of the studies comprising 
this thesis is that 5-HT1A and 5-HT1B receptors have a limited role in the self-
administration of MDMA. If true, this conclusion would suggest that the facilitated 
self-administration produced by RU 29496 pretreatment was due to some non-specific 
effect. To test this possibility, it would be important to co-administer a 5-HT1A or 5-
HT1B receptor antagonist with RU 24969 during pretreatment and test for latency to 
acquire MDMA self-administration. 
Limitations 
It is possible that the conclusions made in this thesis were skewed by the 
behavioural measures used. Although it was demonstrated that RU 24969-produced 
adipsia and 8-OH-DPAT-produced locomotor activity are measures of 5-HT1B and 5-
HT1A receptor activation, respectively, there is no consensus on what population of 5-
HT1B or 5-HT1A receptors produce these effects. Systemic administration of 8-OH-
DPAT produced dose-dependent hyperactivity, but this locomotor response is the net 
result of global 5-HT1A activation. Specific 5-HT1A populations alter locomotor 
activity in different ways, for example local injections of 8-OH-DPAT in the PFC did 
not alter locomotor activity (Solati et al., 2011), while administration in the NAc 
decreased locomotor activity (Hillegaart, Ahlenius, & Larsson, 1991; Plaznik et al., 
1994). Similarly, the population of 5-HT1B receptors responsible for the adipsic 
response to RU 24969 is not known. One study showed that local infusion of RU 
24969, or the more selective 5-HT1B receptor agonist, CP 93129, in the NAc reduced 
responding for water (P. J. Fletcher & Korth, 1999a), but it is not clear what other 
populations of 5-HT1B receptors might also influence this behavioural response. Thus, 





example, that MDMA self-administration did alter some 5-HT1A and/or 5-HT1B 
receptor populations, but not those that impact the locomotor response to 8-OH-DPAT 
or the adipsic response to RU 24969. 
Extensive study would be required to address the possibility that the negative 
results found in this thesis were due to the choice of behavioural responses. Because of 
the time, rats, and drugs required, it was not possible to investigate further for this 
thesis, but our lab has started to probe this possibility in further detail. The logical first 
step is to directly investigate the effect of MDMA self-administration on 5-HT1A and 
5-HT1B receptor binding. There is a widely used and well characterised 5-HT1A 
antibody (Abbas et al., 2007; Kia et al., 1996; Say, Machaalani, & Waters, 2007; 
Tachibana, Endoh, Fujiwara, & Nawa, 2005), allowing for an immunohistochemistry 
investigation, but 5-HT1B receptors are best mapped using a radioactively labelled 
ligand (Domenech, Beleta, & Palacios, 1997; Lindhe et al., 2011). Our lab is currently 
conducting 5-HT1A immunohistochemistry on tissue from rats that have extensive 
MDMA self-administration history. Such an approach allows for a detailed, region 
specific, analysis of the effect of MDMA self-administration. Similar data could be 
obtained to determine the effect of RU 24969 pretreatment. Receptor populations that 
are similarly affected by both manipulations might underlie the development of 
MDMA as an efficacious reinforcer. Thus, local drug administrations in these areas 
could be used, first to obtain a behavioural response to predict the acquisition of 
MDMA self-administration, then for pharmacological treatments to reduce MDMA 
self-administration. 
Validity of MDMA doses 
The self-administration paradigm was used in this thesis because it likely 
produces neuroadaptations similar to those produced by ecstasy use in humans. It is 
important to note that, when compared across species, the MDMA doses self-
administered in this thesis were of relevance to human users. The issue of interspecies 
scaling is based on the fact that, in general, smaller animals have relatively larger 
organs and a shorter blood circulation time, and so will metabolise drug faster 
(Mordenti & Chappell, 1989). Therefore, as long as there are no species-specific 
mechanisms of drug metabolism, smaller animals require larger doses in order for 
effects to be comparable to those produced in larger animals. Most recreational users 





and although the contents of ecstasy tablets procured ‘on the street’ vary widely, 
median MDMA content per tablet has been shown to be around 70-80 mg (Vogels et 
al., 2009). Therefore, a 70kg user is consuming approximately 1-2 mg/kg MDMA in 
recreational settings. Interspecies scaling can help to determine the doses that should 
be administered in animal studies to best mimic the effects of such doses in 
recreational users.  
 As a starting point for investigating drugs across species the USA Food and 
Drug Administration (FDA) suggest that drug doses should be scaled across species 
based on the body weight and surface area of these species (Food and Drug 
Administration, 2005). The FDA recommendation is that the effects of a 1.0 mg/kg 
dose in a human are roughly comparable with the effects of a 6.2 mg/kg dose in a rat. 
The FDA scaling suggestions are not drug-specific and are meant merely as a 
guideline for determining safe initial doses in clinical trials.  
With specific reference to MDMA, some researchers have used the following 
algorithm to scale doses between species: 
DHuman = DAnimal (WHuman / WAnimal) k   (Equation 1) 
where D is the drug dose in mg, W is weight in kg, and k is an estimated value that 
reflects the logarithmic relationship between bodyweight and metabolic rate (that is, 
the slope of the curve fitted to the log transforms of empirical values for weight and 
drug clearance times of different species). This process, in which doses are determined 
by transforming bodyweight to a different physiological variable through a power 
function, is called ‘allometric scaling’ (Mordenti & Chappell, 1989). The precise value 
of the scaling factor, k, has been seriously contended in the literature, with suggestions 
ranging between 0.67 and 0.77 (Food and Drug Administration, 2005; Mordenti & 
Chappell, 1989; Travis & White, 1988; Watanabe, Bois, & Zeise, 1992). In studies 
using MDMA, a k value of 0.7 has been adopted (McCann & Ricaurte, 2001; Ricaurte, 
Yuan, & McCann, 2000). Based on Equation 1, with k set at 0.7, a 1.0 mg/kg dose in a 
70kg human would be equivalent to a 5.0 mg/kg dose in a 330g rat. It should be noted 
that this suggested dose could vary from 3.4 mg/kg to 5.9 mg/kg if the highest or 
lowest suggested k value is used, respectively. 
Vollenweider, Jones, and Baggott (2001) have suggested that allometric scaling 
is not relevant to MDMA because there is evidence for species differences in MDMA 
pharmacokinetics, and because MDMA has active metabolites that may contribute to 





curve (AUC) of MDMA plasma levels) should be compared between species to 
determine similar doses. Based on equation 1, McCann and Ricaurte (2001) claim that 
a 20 mg/kg dose of MDMA in a 220g rat is comparable to a 1.4 mg/kg dose in a 
human, however AUC of MDMA plasma concentrations in humans after 
approximately 1.8 mg/kg was 70% lower than the AUC in rats after 20 mg/kg 
(Vollenweider et al., 2001). Although comparing pharmacokinetic data can account for 
some potential flaws with allometric scaling, comparisons can only be made with 
empirical data, so finding similar doses across species becomes a ‘trial and error’ type 
task.  
Both allometric scaling and comparisons of pharmacokinetic data (AUC) 
suggest that a human dose of approximately 1 mg/kg is comparable to a rat dose of 
roughly 5 mg/kg (De La Torre et al., 2000; Fitzgerald, Blanke, & Poklis, 1990). Thus, 
during initial self-administration sessions, in which rats self-administer less than 5 
infusions per session, rats are consuming less MDMA than a human user might be 
expected to use recreationally. As intake increases, rats will self-administer 5-10 
mg/kg per session, which roughly scales to the human recreational dose. The total 
intake of 350 mg/kg MDMA used in this thesis is comparable to that of a heavy 
ecstasy user, after roughly 70 recreational doses. Most studies have shown cognitive or 
behavioural deficits in ecstasy users to be present at levels of total intake around or 
below 70 doses (Booij et al., 2014; A. K. Davis & Rosenberg, 2014; McCann, Mertl, et 
al., 1999; Wagner et al., 2013). Therefore, the doses of MDMA self-administered by 
rats in this thesis are relevant to human ecstasy users, particularly heavy users.  
Key findings and future directions 
This thesis made a number of novel and important findings. Firstly, 
characterising the adipsic and hyperactive responses to RU 24969 as 5-HT1B and 5-
HT1A receptor mediated, respectively, was important for clarifying previous findings 
and facilitating further research. Earlier studies had not clearly shown the mechanism 
by which RU 24969 produced hyperactivity, and some had interpreted the hyperactive 
response as a behavioural measure of 5-HT1B receptor activation (Callaway & Geyer, 
1992). The results from this thesis clearly show a role of 5-HT1A, but not 5-HT1B 
receptors in RU 24969-produced hyperactivity. Furthermore, this thesis provides a 
straightforward behavioural assay for 5-HT1B receptor activation, and this behavioural 





population of 5-HT1B receptors that produce the the adipsic response to RU 24969 
would make this behavioural assay more useful. 
As one reviewer pointed out, the facilitation of MDMA self-administration 
produced by RU 24969 pretreatment is a ‘novel and important’ finding for the 
addiction field, although more work needs to be done to understand this effect. I would 
strongly encourage further investigation of the effects of RU 24969 pretreatment on 5-
HTergic systems so that the mechanism by which this pretreatment facilitated MDMA 
self-administration can be elucidated. Another novel finding made in this thesis was 
that MDMA self-administration had no effect on behavioural responses to 5-HT1A or 
5-HT1B activation. Again, a reviewer commented that these results are interesting and 
important, even though the results were negative. 
The studies in this thesis were based on the theory that a decreased 5-HTergic 
response to MDMA after repeated exposure could enhance the reinforcing effects of 
MDMA via altered activation of 5-HT receptors that regulate dopamine 
neurotransmission. Although this thesis suggests that 5-HT1A and 5-HT1B receptors 
likely play a limited role in the enhanced reinforcing efficacy of MDMA after repeated 
exposure, the theoretical basis for these studies is still sound. Thus, it is possible that 
there are other 5-HT receptors that regulate the reinforcing efficacy of MDMA and 
that also underlie cognitive and behavioural deficits following repeated exposure. Two 
5-HT receptors that have been shown to regulate dopaminergic neurotransmission are 
the 5-HT2A and 5-HT2C receptors.  
5-HT2C receptors are well localised to mediate the dopaminergic responses to 
drugs of abuse, with high levels of 5-HT2C receptors reported in dopamine terminal 
areas of the PFC, striatum, and NAcc, and in the VTA (Bubar & Cunningham, 2006; 
Clemett, Punhani, Duxon, Blackburn, & Fone, 2000; Di Matteo, De Blasi, Di Giulio, 
& Esposito, 2001; Eberle-­‐Wang, Mikeladze, Uryu, & Chesselet, 1997; Ji et al., 2006). 
5-HT2C receptor agonists inhibited, while 5-HT2C receptor antagonists enhanced, the 
firing rate of VTA dopamine neurons, and extracellular dopamine levels in the nucleus 
accumbens and PFC (Alex, Yavanian, McFarlane, Pluto, & Pehek, 2005; Di Matteo et 
al., 2001).  
The 5-HT2C/2B receptor antagonist, SB 206553, and the more selective  5-HT2C 
receptor antagonist, SB 242084, both potentiated the cocaine-produced increase in 
extracellular dopamine in the nucleus accumbens and striatum (Navailles, De 





inhibited the self-administration of cocaine, ethanol, and nicotine, an effect that was 
reversed by the 5-HT2C receptor antagonist, SB 242084 (P. J. Fletcher, Chintoh, 
Sinyard, & Higgins, 2004; P. J. Fletcher, Rizos, Sinyard, Tampakeras, & Higgins, 
2007; Grottick, Corrigall, & Higgins, 2001; Grottick, Fletcher, & Higgins, 2000; 
Tomkins et al., 2002). Mice that lack the 5-HT2C gene reached higher breakpoints in a 
progressive ratio paradigm reinforced by cocaine, and also showed enhanced levels of 
cocaine-induced dopamine release in the NAcc (Rocha et al., 2002). 
These findings are consistent with the idea that activation of 5-HT2C receptors 
is inhibitory to, while blockade of 5-HT2C receptors facilitates, the dopaminergic 
response to drugs of abuse. As such, it is possible that a down-regulation of 5-HT2C 
receptors, in response to repeated exposure to MDMA, underlies the development of 
MDMA as an efficacious reinforcer 
Unfortunately, there is no clear evidence for 5-HT2C receptor down-regulation 
in response to MDMA exposure. On the one hand, male ecstasy users showed blunted 
neuroendocrine responses to the 5-HT2/1A receptor agonist, m-CPP, compared to 
MDMA-naïve controls (McCann, Eligulashvili, Mertl, Murphy, & Ricaurte, 1999), 
and repeated administration of MDMA decreased 5-HT2C receptor protein levels in the 
hippocampus of young-adult rats (García-Cabrerizo & García-Fuster, 2015), 
suggesting a possible down-regulation of 5-HT2C receptors after MDMA exposure. On 
the other hand, repeated exposure to MDMA enhanced the inhibition of MDMA-
produced hyperlocomotion by the 5-HT2C receptor agonist, MK 212 (Ramos, Goni-
Allo, & Aguirre, 2005) and increased sensitivity to the 5-HT2/1A receptor agonist, m-
CPP (Taffe et al., 2002). Furthermore, repeated exposure to MDMA increased 5-HT2C 
mRNA in cortex and hypothalamus (Kindlundh-Högberg et al., 2006). Further still, 
some animal studies have failed to show any effect of MDMA exposure on 
neuroendocrine or behavioural responses to m-CPP (Bull et al., 2003; Jones, Brennan, 
Colussi-Mas, & Schenk, 2010). 
It is entirely possible that repeated exposure to MDMA in the self-
administration paradigm would down-regulate 5-HT2C receptors, but so far there is 
limited evidence to suggest this would be the case. Significantly more research is 
required to determine the effects of MDMA self-administration on 5-HT2C receptor 
mechanisms. On the other hand, there is substantial evidence to suggest that 
neuroadaptations in 5-HT2A receptor mechanisms might underlie the development of 






5-HT2A receptors are strongly expressed as excitatory 5-HTergic receptors on 
non-5-HTergic cells in the PFC (Eison & Mullins, 1995), where their activation has 
been shown to increase dopamine activity in the VTA (Bortolozzi, Díaz-Mataix, 
Scorza, Celada, & Artigas, 2005). This increased mesocorticolimbic dopamine release 
is a product of increased glutamatergic activity in projections from the PFC to the 
VTA (Aghajanian & Marek, 1999; Pehek, Nocjar, Roth, Byrd, & Mabrouk, 2005). The 
5-HT2A/2C receptor antagonist, ketanserin, attenuated the dopaminergic response to 
MDMA in the striatum (Nash, 1990), and a similar effect was produced by local 
administration of the selective 5-HT2A receptor antagonist, M100907, in the striatum 
(Schmidt, Sullivan, & Fedayal, 1994). On the other hand the non-selective 5-HT2 
receptor agonists, DOI and 5-MeODMT, both enhanced the dopaminergic response to 
MDMA in the striatum (Gudelsky, Yamamoto, & Nash, 1994). These data suggest that 
activation of the 5-HT2A receptor via MDMA-induced 5-HT release would enhance the 
reinforcing efficacy of MDMA.  
Compellingly, repeated MDMA was associated with increased 5-HT2A receptor 
binding (Benningfield & Cowan, 2013; Urban et al., 2012)(but see McGregor et al. 
(2003)), suggesting that MDMA self-administration might also up-regulate 5-HT2A 
receptors. Thus, with repeated exposure to MDMA, enhanced activation of 5-HT2A 
receptors could underlie the development of MDMA as an efficacious reinforcer. This 
hypothesis is in agreement with the finding that a neurotoxic 5,7-DHT lesion, which 
also facilitated the acquisition of MDMA self-administration (Bradbury et al., 2014), 
produced an increase in 5-HT2A receptor binding density in mice (Heal, Philpot, 
Molyneux, & Metz, 1985). 
An up-regulation of 5-HT2A receptors might also underlie the increased 
impulsivity produced by repeated exposure to MDMA. The 5-HT2A/2C receptor agonist, 
DOI, increased premature responding on the 5CSRTT (Koskinen, Haapalinna, & Sirvi, 
2003; Koskinen & Sirviö, 2001), and this effect was blocked by the 5-HT2A/2C receptor 
antagonist, ketanserin (Koskinen, Ruotsalainen, Puumala, et al., 2000; Koskinen, 
Ruotsalainen, & Sirviö, 2000), while ketanserin (P. J. Fletcher, Tampakeras, Sinyard, 
& Higgins, 2007; Passetti, Dalley, & Robbins, 2003; Ruotsalainen et al., 1997; Talpos, 
Wilkinson, & Robbins, 2006) and the more selective 5-HT2A receptor antagonist, 
M100907 (P. J. Fletcher, Tampakeras, et al., 2007; Winstanley, Theobald, Dalley, 





similar 1CSRTT (Anastasio et al., 2011). Increased impulsivity, due to an up-
regulation of 5-HT2A receptors after repeated exposure to MDMA,  would be expected 
to facilitate drug taking, and as such could underlie the development of an MDMA 
SUD (Schenk & Aronsen, 2015). 
The role of the 5-HT2A receptor in MDMA self-administration has not been 
studied. Some studies have shown no effect of regular, repeated MDMA 
administration on the head-twitch or locomotor responses to the 5-HT2A/2C receptor 
agonist, DOI (Granoff & Ashby Jr, 1998), or the behavioural response to the non-
selective 5-HT2 receptor agonist, mCPP (Jones et al., 2010). On the other hand, an 
intermittent dosing regimen of MDMA increased the head-twitch responses to DOI 
(Biezonski et al., 2009), suggesting that adaptations in 5-HT2A receptors may be 
dependent on dosing regimen. Ecstasy use is typically intermittent, and 5-HT2A 
binding was increased in human ecstasy users, compared to naïve controls, with 
increased exposure to MDMA associated with increased 5-HT2A binding density (Di 
Iorio et al., 2012; Urban et al., 2012). Thus, it is possible that an up-regulation of 5-
HT2A receptors would be evident after MDMA self-administration.  
It would be interesting to selectively up-regulate 5-HT2A receptors and test for 
latency to acquire MDMA self-administration. An up-regulation may be achieved by 
repeatedly administering the selective 5-HT2A receptor antagonist, M100907 (Minabe, 
Hashimoto, Watanabe, & Ashby, 2001). Behavioural assessment is difficult, however, 
because of the lack of selective 5-HT2A receptor agonists. Ideally, a behavioural 
response to the selective antagonist, M100907, would be determined. There are some 
reports that M100907 enhanced the inhibition of a startle response in the pre-pulse 
inhibition paradigm (Padich, McCloskey, & Kehne, 1996; Zhang, Engel, Jackson, 
Johansson, & Svensson, 1997), although more parametric work for this behavioural 
response is required (Geyer, Krebs-Thomson, & Varty, 1999; Varty, Bakshi, & Geyer, 
1999) 
Conclusion 
 Repeated exposure to MDMA enhances the reinforcing efficacy of MDMA. It 
is possible that this increased reinforcement is due to adaptations in 5-HT receptors 
that regulate dopaminergic responses to MDMA. This thesis showed that 5-HT1A and 
5-HT1B receptors likely play a limited role in the self-administration of MDMA, and 





exposure. Future research should consider the role of the 5-HT2A receptor in 
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